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Abbreviations	
	AHC	 acute	hepatitis	C	ALT	 alanine-aminotransferase	CHC	 chronic	hepatitis	C	DAA	 direct-acting	antivirals	DNA	 deoxyribonucleic	acid	GAA	 gamma-activation	sequence	GSEA	 gene	set	enrichment	analysis	GWAS	 genome-wide	association	study	HCC	 hepatocellular	carcinoma	HCV	 hepatitis	C	virus	IFNαR	 Interferon	alpha	receptor	IFN-α	 Interferon	alpha	IFN-γ	 Interferon	gamma	IFN-λ	 Interferon	lambda	IRF	 Interferon	regulatory	factor	IRS	 internal	ribosome	entry	site	ISG	 Interferon	stimulated	gene	ISRE	 IFN-stimulated	response	element	Jak	 Janus	kinase	lncRNA	 Long	non-coding	RNA	MAVS	 mitochondrial	antiviral	signaling	protein	mRNA	 messenger	RNA	miRNA	 microRNA	PAMP	 pathogen-associated	molecular	pattern	PBMC	 peripheral	blood	mononuclear	cell	pegIFNα	 pegylated	Interferon	alpha	pSTAT1	 phosphorylated	STAT1	RNA	 ribonucleic	acid	SNP	 single	nucleotide	polymorphism	SOCS	 suppressor	of	cytokine	signaling	STAT	 signal	transducer	and	activator	of	transcription	SVR	 sustained	virologic	response	TLR	 toll-like	receptor	TRIF	 TIR-domain-containing	adapter-inducing	interferon-β	USP18	 Ubiquitin-specific	peptidase	18	
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Summary	
	Because	of	its	worldwide	impact	on	human	health,	hepatitis	C	virus	(HCV)	is	among	the	most	 intensively	studied	human	pathogens.	Humans	are	 the	only	natural	host	 for	HCV	and	chimpanzees	the	only	animal	model.	Therefore,	HCV	research	is	mostly	restricted	to	in	vitro	 systems.	 In	particular,	 a	 robust	 in	vitro	HCV	 infection	 system	has	enabled	 the	accumulation	of	an	impressive	body	of	knowledge	on	basic	HCV	biology	and	viral-host	interactions	 in	 vitro.	 Not	 unexpectedly	 however,	 little	 research	 on	 the	 host-virus	interaction	and	the	 impact	of	antiviral	 therapy	in	the	human	liver	has	been	performed	mostly	due	to	the	challenges	and	difficulties	associated	with	collection	and	sampling	of	appropriate	human	liver	tissue.			In	the	first	part	of	our	work	we	investigated	the	impact	of	HCV	infection	on	the	cellular	homeostasis	of	hepatocytes	in	vivo.	The	challenge	for	such	an	analysis	lies	in	separating	direct	 responses	 to	 viral	 infection	 in	 the	 infected	 hepatocytes	 from	 the	 innate	 and	adaptive	immune	responses	associated	with	HCV	infection.	Furthermore,	the	strength	of	the	 immune	response	varies	considerable	 from	patient	 to	patient	 further	complicating	separation	 of	 direct	 and	 indirect	 responses	 to	 HCV	 infection.	 We	 therefore	 carefully	selected	 a	 set	 of	 biopsies	 without	 detectable	 immune	 response	 and	 compared	 high-throughput	transcriptome	sequencing	profiles	of	these	biopsies	with	biopsies	from	non-infected	patients.	These	studies	revealed	that	gene	expression	changes	mainly	reflect	the	presence	 of	 immune	 cell	 infiltrates	 in	 the	 HCV	 group	 without	 detectable	 immune	response.	 However,	 HCV	 infection	 does	 not	 trigger	 any	 significant	 gene	 expression	changes	 in	 the	 infected	 cells	 suggesting	 that	 many	 of	 the	 HCV	 induced	 changes	previously	 observed	 in	 vitro	 do	 not	 occur	 in	 the	 HCV-infected	 liver.	 This	 discrepancy	most	 likely	 is	 a	 reflection	 of	 the	 much	 higher	 viral	 RNA	 content	 per	 cell	 typically	observed	 in	 in	vitro	systems	compared	to	 the	viral	 load	 in	 the	hepatocytes	 in	 the	HCV	infected	liver.		In	the	second	part	we	investigated	a	long-standing	conundrum	in	the	field	regarding	the	inability	of	the	endogenous	IFN	system	activation	to	eradicate	HCV	infections.	Interferon	alpha	(IFNα)	has	been	the	backbone	of	anti-HCV	therapy	for	the	last	25	years.	Till	today	it	 is	unclear,	why	recombinant	IFNα	injected	during	therapies	 is	a	potent	antiviral	and	eradicates	HCV	in	about	50%	of	patients,	whereas	the	activation	of	the	endogenous	IFN	
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system	in	the	liver	is	ineffective.	We	performed	an	in-depth	transcriptome	analysis	of	a	unique	set	of	paired	liver	biopsies,	obtained	before	and	at	different	time	points	during	the	 first	 week	 of	 antiviral	 therapy	 using	 pegylated	 interferon	 alpha	 (pegIFNα).	 Our	analysis	provides	strong	evidence	that	quantitative	rather	than	qualitative	differences	in	gene	induction	are	responsible	for	the	failure	of	the	endogenous	IFNs	and	the	success	of	pegIFNα	in	viral	eradication	Finally	the	role	of	miR-122	and	other	non-coding	RNAs	in	response	to	HCV	infection	and	to	IFNα	therapy	in	the	liver	was	investigated.	In	vitro	studies	have	shown	that	binding	of	miR-122	by	HCV	can	regulate	host	gene	expression	by	reducing	(sponging)	the	amount	of	 miR-122	 available	 for	 gene	 repression1.	 We	 find	 that	 miR-122	 targets	 are	 not	significantly	up-regulated	in	response	to	HCV	infection	in	the	human	liver.	However,	we	show	 that	 the	precursor	 transcript	 of	miR-122,	 as	well	 as	 other	 long	non-coding	RNA	transcripts	that	act	as	precursors	for	miRNAs,	are	down-regulated	in	the	 infected	liver	during	peg	IFNα/ribavirin	treatment.	These	results	suggest	that	the	down-regulation	of	miRNAs	could	contribute	to	peg	IFNα/ribavirin-mediated	clearance	of	HCV	infection.				 	
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1. Introduction	
	1.1. Hepatitis	C	Infection		1.1.1. Epidemiology	and	natural	history		HCV	infections	are	a	major	cause	of	liver-related	morbidity	and	mortality.	An	estimated	160	million	persons	are	chronically	HCV	infected	worldwide	and	are	at	increased	risk	of	developing	 liver	 fibrosis,	 cirrhosis	 and	 hepatocellular	 carcinoma2.	 HCV	 was	characterized	in	1989	using	a	novel	experimental	approach	in	which	a	cDNA	expression	library	 that	 had	 been	 constructed	 from	 the	 plasma	 of	 a	 patient	with	 post-transfusion	non-A,	non-B	hepatitis	was	screened	 for	 the	unidentified	agent3.	Populations	at	risk	of	acute	 hepatitis	 C	 were	 patients	 who	 received	 blood	 products	 prior	 to	 1990,	 before	routine	 screening	 of	 blood	 products	 for	 HCV.	 Thus,	 in	 Europe	 and	 the	 USA,	 sero-prevalence	 increases	 with	 age	 and	 peaks	 in	 55–64	 year	 old	 patients4.	 Since	 the	introduction	of	routine	screening	of	blood	products	and	sterile	injection	needles	in	the	1990s,	 the	 principal	 cohorts	 of	 newly	 infected	 patients	 has	 changed.	 The	majority	 of	patients	 presenting	 as	 new	 cases	 in	 developed	 countries	 now	 are	 people	 who	 inject	drugs	 and	 men	 who	 have	 sex	 with	 men5.	 Despite	 considerable	 research	 efforts,	 a	prophylactic	vaccine	is	still	not	available.		The	acute	phase	is	often	clinically	mild	and	therefore	rarely	diagnosed.	(Figure	1).	The	initial	 features	 are	 non-specific	 flu-like	 symptoms,	 while	 more	 specific	 viral	 hepatitis	symptoms	 such	 as	 jaundice,	 dark	 urine	 and	 abdominal	 discomfort	 only	 occur	 in	 a	minority	 of	 individuals.	 Accurate	 studies	 of	 the	 time	 course	 for	 clearance	 of	 acute	hepatitis	 C	 infection	 are	 difficult	 to	 carry	 out	 because	 of	 the	 silent	 onset	 of	 the	 acute	disease.	In	the	available	studies,	the	rate	of	spontaneous	resolution	of	HCV	infections	is	reported	to	be	between	15–40%6,	7,	8.		Chronic	HCV	infection	is	defined	as	persistence	of	HCV	RNA	in	the	blood	for	more	than	six	months.	 Chronic	hepatitis	 is	 the	most	 common	outcome	of	HCV	 infection	 and	may	lead	 to	 fibrosis	 and	 cirrhosis	 of	 the	 liver.	 It	 is	 generally	 a	 slowly	 progressive	 disease	characterized	 by	 persistent	 hepatic	 inflammation	 leading	 to	 the	 development	 of	cirrhosis	 in	 approximately	 15–25%	 of	 patients	 over	 20–30	 years	 of	 HCV	 infection.	(Published	data	are	highly	variable	with	progression	 rates	 to	 cirrhosis	between	2–3%	
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and	 51%	 over	 22	 years9,	10.)	 Development	 of	 hepatic	 fibrosis	 in	 hepatitis	 C	 is	 multi-factorial	 with	 many	 co-factors,	 such	 as	 age	 at	 infection,	 male	 gender,	 alcohol	consumption,	obesity,	insulin	resistance,	type	2	diabetes,	co-infection	with	hepatitis	B	or	HIV,	 immunosuppressive	 therapy	 or	 genetic	 factors	 potentially	 increasing	 an	individual’s	risk	of	developing	significant	fibrosis	or	cirrhosis11.	Spontaneous	clearance	in	 the	 chronic	phase	of	 infection	 is	 extremely	 rare12.	Once	 cirrhosis	 is	 established,	 the	disease	 progression	 remains	 unpredictable:	 cirrhosis	 can	 remain	 indolent	 for	 many	years	in	some	patients	whilst	progressing	in	others	to	hepatocellular	carcinoma,	hepatic	decompensation	and	death.	Hepatic	decompensation	occurs	at	a	rate	of	3-6	%	per	year,	and	 decompensated	 cirrhosis	 has	 a	 annual	mortality	 rate	 of	 15-20%13.	 HCC	 develops	with	 an	 annual	 rate	 of	 1-5%.	 Successful	 treatment	 of	 CHC	 results	 in	 marked	improvements	in	liver	inflammation	and	in	fibrosis	stage14.		Since	the	majority	of	the	people	with	persistent	infection	are	unaware	of	the	infection,	screening	 programs	 will	 be	 required	 to	 identify	 patients	 and	 to	 prevent	 silent	progression	of	the	disease2,	4.	Given	the	lack	of	a	vaccine,	the	burden	of	disease	and	the	high	 number	 of	 chronically	 infected	 individuals,	 successful	 antiviral	 treatment	will	 no	doubt	be	an	integral	part	of	controlling	this	disease.				
	
	
Figure	1:	Natural	history	of	CHC15					
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1.1.2. HCV	structure	and	life	cycle		HCV	 is	an	enveloped	positive-strand	RNA	virus	belonging	 to	 the	 family	of	Flaviviridae	and	only	infects	humans	and	chimpanzees.		Hepatocytes	are	the	main	target	cell	for	HCV,	although	low	level	infection	of	cells	of	the	immune	system	has	also	been	reported16.	HCV	infection	 is	 a	 highly	 dynamic	 process	 with	 a	 viral	 half-life	 of	 only	 a	 few	 hours	 and	production	and	 clearance	of	 an	estimated	1012	 virions	per	day	 in	 a	 given	 individual17.	This	high	replicative	activity	as	well	as	the	high	error	rate	of	 the	viral	RNA-dependent	RNA	 polymerase	 are	 responsible	 for	 the	 broad	 genetic	 variability	 of	 the	 isolated	HCV	samples	 recognized	 as	 viral	 quasispecies18.	 Phylogenetic	 analysis	 of	 HCV	 isolates	enabled	viral	classification	into	seven	major	genotypes	and	more	than	100	subtypes19.		The	HCV	genome	is	a	9.6kb	positive-strand	RNA	molecule	that	is	composed	of	a	5'-non-coding	 region	 (NCR)	 containing	 an	 internal	 ribosome	 entry	 site	 (IRES)	 that	 drives	translation	 of	 a	 single	 open	 reading	 frame	 encoding	 the	 structural	 as	 well	 as	 non-structural	proteins	and	is	followed	by	a	3'-NCR.	(Figure	2).	The	polyprotein	is	cleaved	by	cellular	 and	 viral	 proteases	 to	 yield	 the	 structural	 core	 protein	 and	 envelope	glycoproteins	E1	and	E2	that	form	the	viral	particle	and	seven	non-structural	proteins.	The	 non-structural	 proteins	 include	 the	 p7	 ion	 channel,	 the	 NS2-3	 protease,	 the	 NS3	serine	protease	and	RNA	helicase,	 the	NS4A	polypeptide,	 the	NS4B	and	NS5A	proteins	and	the	NS5B	RNA-dependent	RNA	polymerase	(RdRp)20.		
	
Figure	2:	Structure	of	HCV20			
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The	 HCV	 life	 cycle	 is	 only	 partly	 understood.	 Briefly,	 as	 shown	 in	 Figure	 3,	 the	 HCV	virion	circulates	in	the	bloodstream	either	as	a	free	particle	or	surrounded	by	host	low-density	lipoproteins21,	attaches	onto	the	target	cell	membrane	by	sequential	binding	of	various	receptor	molecules,	and	enters	into	the	cell	by	a	clathrin-mediated	endocytosis	process.	 Disruption	 of	 the	 viral	 capsid	 in	 the	 endocytic	 compartment	 releases	 RNA	genome	 of	 positive	 polarity	 into	 the	 cytoplasm.	 Upon	 virus	 uncoating	 the	 IRES-dependent	translation	of	HCV	proteins	is	initiated	on	the	template	of	the	viral	genome.	HCV	non-structural	proteins	assemble	into	replication	complexes	on	the	membranes	of	the	 endoplasmic	 reticulum,	 inducing	 formation	 of	 specific	 structures	 known	 as	membranous	 web22,	23.	 	 The	 positive-strand	 RNA	 is	 copied	 by	 the	 NS5B	 RdRp	 into	 a	negative-strand	intermediate	forming	a	double-strand	replicative	form,	which	serves	as	template	 for	 the	 production	 of	 new	 positive-strand	 genomes.	 Newly	 synthesized	positive-strand	viral	RNA	translocates	to	the	surface	of	the	lipid	droplets,	where	virion	assembly	 takes	 place24,	25,	26.	 The	 viral	 particles	 leave	 the	 cell	 in	 a	 complex	with	 lipids	making	use	of	the	very-low-density	lipoproteins	secretion	pathway21,	27,	28.				
	
Figure	3:	Lifecycle	of	HCV20.	Virus	binding	and	internalization	(a);	cytoplasmic	release	and	uncoating	(b);	IRES-mediated	translation	and	polyprotein	processing	(c);	RNA	replication	(d);	packaging	and	assembly	(e);	virion	maturation	and	release	(f).		
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Several	host	 cell	 factors	are	 required	 for	virus	 translation,	 replication	and	production.	These	 include	 liver-specific	 microRNA-122	 (miR-122),	 which	 was	 shown	 to	 interact	with	the	5'-NCR	of	the	HCV	genome	and	increase	HCV	abundance	in		replicon		models	29.	miR-122	 	was	 	 also	 	 implicated	 	 in	 HCV	 	 translation,	 	 reportedly	 	 by	 	 enhancing	 	 the		association	 	 of	 	 ribosomes	 	 with	 	 the	 viral	 RNA30.	 miR-122	 associates	 with	 host	Argonaute	2	to	bind	the	HCV	RNA,	and	through	this	interaction	stabilizes	the	viral	RNA31	and	most	 likely	protects	 its	 5’-NCR	 from	degradation32.	 It	was	 reported,	 that	HCV	has	also	sponge	effect	in	depleting	the	host	cell	for	miR-122	resulting	in	global	derepression	of	host	miR-122	targets1.		1.1.3. Model	systems	in	Hepatitis	C		Because	 of	 their	 substantial	 impact	 on	 human	 health,	 HCV	 infections	 have	 been	extensively	 studied	 and	 became	widely	 used	model	 systems	 to	 investigate	 host-virus	interactions33.	
In	vitro	models	Since	the	discovery	of	HCV	in	19893,	the	lack	of	a	suitable	cell	culture	and	small	animal	model	 systems	 represented	 a	major	 obstacle	 in	 studying	 the	 biology	 of	 the	 virus	 and	developing	 prophylactic	 and	 therapeutic	 interventions.	 Patient-derived	 HCV	 isolates	failed	to	initiate	productive	infection	in	cell	culture.	In	1997	HCV	molecular	clones	that	were	 infectious	 in	chimpanzees	were	developed,	however	 these	viral	genomes	did	not	produce	 viral	 particles	 in	 cell	 culture34,	 35.	 In	 1999,	 the	 group	 of	 Bartenschlager	developed	 an	 efficient	 cell	 culture	 replication	 model	 of	 HCV.	 These	 HCV	 replicons	contained	adaptive	mutations	 that	prevented	productive	 replication	 in	 chimpanzees36.	Moreover,	 the	 system	 did	 not	 support	 the	 full	 viral	 life	 cycle	 and	 did	 not	 produce	infectious	 viruses.	 The	 breakthrough	 came	 with	 the	 serendipitous	 discovery	 that	 an	isolate	from	a	Japanese	patient	with	fulminant	hepatitis	could	replicate	in	Huh7	derived	cell	lines	without	the	requirement	for	cell	culture	adaptive	mutations	and	produced	fully	infectious	 viral	 particles	 that	 were	 infectious	 in	 chimpanzees37,	 38,	 39.	 Following	 this	initial	 observations,	 a	 number	 of	 improved	 derivates	 of	 the	 original	 genotype	 2a	HCV	clone	have	been	generated	 and	 successfully	 tested	 in	 additional	 cell	 culture	model.	Of	note,	primary	human	hepatocytes	can	also	be	infected,	albeit	with	much	lower	efficiency	of	 infection	 and	 replication,	 and	 are	 considered	 to	 represent	 a	 more	 physiological	experimental	 system40,	41,	42.	However,	 poor	 availability	 of	 these	 cells,	 high	 costs,	 short	survival	 (up	 to	2	weeks)	 and	 the	 relative	poor	permissiveness	 for	HCV	 infection	have	
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limited	 HCV	 studies	 in	 PHH.	 Recently,	 hepatocyte-like	 cells	 derived	 from	 induced	pluripotent	stem	cells	(iPSC)	and	human	embryonic	stem	cells	(hESC)	have	been	shown	to	 be	 susceptible	 to	 HCV	 infection	 and	 could	 potentially	 offer	 improved	 in	 vitro	 HCV	infection	systems	in	the	future43,	44.		
In	vivo	models	Besides	humans,	experimental	infection	of	chimpanzees	has	played	a	pivotal	role	in	the	discovery	 and	 characterization	 of	 HCV	 and	 deciphering	 host-virus	 interactions,	particularly	 cellular	 immunity,	 and	 also	 preclinical	 testing	 of	 antiviral	 treatment	strategies45.	However,	contrary	to	humans,	only	very	few	chimpanzees	develop	chronic	HCV	 infection	 and	 to	 date	 no	 fibrosis	 and	 only	 one	 case	 of	 HCC	 has	 been	 observed.	Furthermore,	studies	involving	chimpanzees	are	very	restricted	due	to	growing	ethical	constraints,	limited	availability	and	high	costs.	Thus,	a	continuous	effort	in	establishing	alternative	animal	model	systems	for	HCV	infection	is	ongoing.			Alternatives	to	humans	and	chimpanzees	 for	the	study	of	HCV	biology	 in	vivo	could	be	found	 in	HCV-related	viruses	 that	 infect	other	 species	 (HCV	homologs)46,	47	 (Figure	4).	However,	it	remains	to	be	examined	whether	the	pathogenesis	of	these	viruses	parallels	that	 seen	 for	 HCV	 in	 humans.	 Besides	 exploring	 viral	 homologs	 as	 an	 HCV	 model,	generating	 a	 mouse	 model	 that	 fully	 supports	 HCV	 infection	 has	 been	 extensively	pursued	 for	many	 years48.	 These	 efforts	 include	 complementary	 approaches	 including	adapting	 HCV	 to	 the	 mouse	 liver,	 establishing	 HCV	 replicating	 transgenic	 mice	 and	establishing	human	xenograft	mice	that	would	not	only	allow	to	study	HCV	infection	but	also	 the	 human	 immune	 response	 to	 the	 infection49,	 50,	 51	 (Figure	 4).	 Despite	 these	efforts,	 no	 robust	 and	 reliable	 small	 animal	 model	 of	 HCV	 infection	 has	 yet	 been	reported.		
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Figure	4:	Different	approaches	to	study	HCV	in	animal	models48.		
First	panel:	HCV-related	viruses	that	infect	animal	species	such	as	wild	mice,	rats,	tamarins,	bats	
and	horses.	These	infections	can	be	studied	in	their	natural	host,	or	eventually	immune	
competent	laboratory	inbred	mouse	strains.	Second	panel:	in	vitro	adaptation	of	HCV	to	mouse	
hepatoma	cells	may	allow	the	isolation	of	viral	variants	that	can	establish	an	infection	in	wild	
type	mice.	Third	panel:	transient	or	stable	expression	of	human	factors	that	are	essential	to	
support	infection	of	wild	type	HCV.	Fourth	panel:	in	xenotransplantation	models,	the	genetic	
background	of	the	host	permits	repopulation	of	the	liver	upon	transplantation	of	human	
hepatocytes.	Additional	transplantation	of	HLA-compatible	hematopoietic	stem	cells	results	in	
dually	reconstituted	mice.		Given	 the	 difficulties	 of	 working	 with	 and	 lack	 of	 suitable	 animal	 models,	 it	 is	 not	surprising	 that	 HCV-host	 cell	 interactions	 have	 been	 mainly	 studied	 in	 cell	 culture	systems,	and	that	only	few	of	these	findings	have	been	evaluated	in	the	human	liver.		1.1.5.	Treatment		The	 main	 goal	 of	 treatment	 for	 chronic	 HCV	 is	 cure,	 and	 thus	 prevention	 of	 disease	progression.	 Sustained	 virological	 response	 (SVR),	 defined	 as	 undetectable	 HCV	 RNA	12–24	weeks	after	completion	of	antiviral	therapy	is	associated	with	reduction	of	both	all-cause	and	liver-related	mortality	from	HCV52.		For	the	past	25	years,	recombinant	interferon-α	(IFNα)	has	been	the	main	component	of	HCV	 antiviral	 therapy.	 Treatment	 efficacy	 improved	 stepwise	with	 pegylation	 of	 IFNα	and	 its	 combination	 with	 other	 antiviral	 drugs15.	 However,	 low	 SVR	 rate	 of	 ~50%,	depending	 on	 genotype	 and	 substantial	 drug	 toxicity	 limited	 the	 efficacy	 of	 this	
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treatment53.	The	introduction	of	direct-acting	antiviral	drugs	(DAAs),	with	two	protease	inhibitor	(PI)	drugs	licensed	in	2011,	has	increased	the	number	of	patients	who	respond	to	treatment,	and	marks	a	new	era	of	HCV	therapy54,	55,	56	(Figure	5).			
	
Figure	5:	Changes	in	standard	of	care	for	HCV,	and	improvements	in	numbers	of	sustained	virological	responses15		Early	use	of	recombinant	IFN	monotherapy	Already	in	1986,	before	HCV	was	cloned,	the	therapeutic	efficacy	of	recombinant	human	IFNα	 was	 shown	 in	 a	 pilot	 study	 of	 ten	 patients	 with	 NANBH57.	 In	 the	 first	 two	randomized	controlled	 trials	recombinant	 IFNα	was	 injected	at	doses	of	1	 to	3	million	units	three	times	per	week	for	24	weeks.	In	only	10-25%	of	patients	sustained	alanine	transaminase	 (ALT)	normalization	occurred58,	59.	Of	note,	 the	 response	 to	 treatment	 in	these	early	 trials	was	assessed	by	measuring	ALT	 levels	 in	 the	serum,	which	 reflected	the	 biochemical	 response	 to	 HCV	 infection.	 It	 was	 only	 in	 1989	 that	 the	 molecular	cloning	 of	 HCV	 made	 it	 possible	 to	 develop	 polymerase	 chain	 reaction	 (PCR)-based	assays	to	measure	the	viral	load	in	the	serum	instead.	Virological	 responses	 to	 IFNα-based	 treatments,	 depending	 on	 measured	 HCV	 RNA	levels	 in	 the	serum,	classified	 into	 three	general	groups:	non-response	(including	null-response	and	partial	 response);	on-treatment	 response	and	relapse;	and	on-treatment	response	with	SVR	after	treatment	(Figure	6)15.			
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Figure	6:	Virological	response	to	IFN-based	treatment15.		
After	12	weeks	of	treatment	of	CHC	with	a	combination	of	pegIFNα	and	ribavirin,	some	patients	
show	a	less	than	2	log	decrease	in	the	titres	of	HCV,	as	measured	in	international	units	(IU)	per	
ml	of	serum,	which	is	classified	as	a	'null	response'.	These	patients	are	considered	to	be	true	non-
responders	to	pegIFNα	treatment.	Partial	responders	have	a	decrease	in	viral	load	of	more	than	
2	log	IU	per	ml	at	the	same	time	point,	but	HCV	RNA	remains	detectable	in	the	serum	
throughout	the	entire	period	of	time	that	they	are	being	treated.	Both	null-responders	and	
partial	responders	are	classified	together	as	non-responders.	Relapsing	patients	have	
undetectable	levels	of	HCV	RNA	in	the	serum	during	their	treatment	but	become	positive	for	
HCV	RNA	after	the	end	of	their	treatment.	A	SVR	is	determined	by	a	lack	of	detectable	HCV	RNA	
levels	in	the	serum	of	patients	for	6	months	after	treatment.	Patients	with	an	early	virological	
response	test	negative	for	HCV	RNA	after	week	12	of	treatment	and	have	more	than	75%	
probability	of	generating	an	SVR.	Patients	with	a	rapid	virological	response	test	negative	for	
HCV	RNA	after	4	weeks	of	treatment	and	have	more	than	a	90%	chance	of	generating	an	SVR.		Combination	of	IFN	and	Ribavirin	(RBV)	Ribavirin	 is	 a	 nucleoside	 analogue	with	 a	 known	broad	 range	 of	 antiviral	 activities.	 It	had	already	been	tested	as	a	monotherapy	for	CHC	in	the	early	1990s	and	was	found	to	transiently	reduce	ALT	levels	during	treatment.	In	1998	the	first	randomized	controlled	trial	that	included	912	patients	showed	that	the	combination	of	subcutaneously	injected	IFNα2b	 with	 daily	 oral	 administration	 of	 RBV	 achieved	 an	 SVR	 in	 38%	 of	 treated	patients,	 which	 was	 an	 increase	 of	 more	 than	 20%	 compared	 with	 IFNα2b	monotherapy60.	After	 this	 study	 the	 combination	of	 IFNα2b	and	RBV	became	 the	new	standard	of	care.	However,	it	still	remains	unclear	how	RBV	boosts	the	response	to	IFNα.		
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Pegylated	IFNα	Pegylation	 of	 IFNa	 by	 attaching	 a	 polyethyleneglycol	molecule	 significantly	 improved	the	half-life	and	thus	the	pharmacokinetics	of	IFNa	without	any	loss	in	biological	activity	53,	54.	This	allowed	for	a	reduction	of	the	injection	frequency	from	daily	to	weekly	and	at	the	same	time	increased	the	antiviral	efficacy	of	IFNα	by	about	another	10–15%61.	It	is	assumed,	 that	 the	 sustained	 high	 serum	 concentration	 of	 pegIFNα	 provide	 for	interrupted	 antiviral	 activity	 through	 a	 permanent	 stimulation	 of	 the	 IFN	 signaling	pathways,	 whereas	 the	 serum	 concentrations	 of	 standard	 IFN-α	 (with	 an	 elimination	half-life	 of	 4	 to	10	hours)	decline	below	pharmacologically	 active	 levels	 in	 the	 second	half	of	each	48-hour	dosing	interval61	62.	However,	there	is	no	experimental	evidence	to	support	this	hypothesis.	On	the	contrary,	IFNα-induced	signalling	through	the	JAK–STAT	pathway	 becomes	 refractory	 in	 a	 matter	 of	 hours63,	 and	 in	 mice	 hepatocytes	 remain	unresponsive	 to	 further	 stimulation	 with	 high	 doses	 of	 IFNα	 for	 several	 days64,	 65.	Whatever	the	mechanisms,	pegIFNα	was	significantly	more	effective	and	in	combination	with	ribavirin	achieved	SVRs	of	56%	of	treated	patients,	an	increase	of	>	10	%	compared	to	conventional	IFNα2a.	54.	In	2002,	the	combination	of	pegIFNα	with	ribavirin	for	6	to	12	months	therefore	became	the	standard	of	care	protocol	for	the	subsequent	decade.			Direct-acting	antiviral	agents	(DAAs)	In	the	last	years,	pegIFNα	and	ribavirin	have	been	gradually	replaced	by	a	new	and	very	potent	 class	 of	 	 DAAs.	 In	 contrast	 to	 IFN	 α,	which	 induces	 the	 body's	 innate	 antiviral	immune	 response,	DAAs	are	designed	 to	directly	 inhibit	 viral	proteins	 involved	 in	 the	HCV	life	cycle.	Three	important	HCV	DAA	classes	are	highlighted:	(1)	NS3/4A	protease	inhibitors,	which	 inhibit	HCV	polyprotein	processing,	 (2)	NS5B	polymerase	 inhibitors,	which	 inhibit	 HCV	 RNA	 replication,	 and	 (3)	 NS5A	 inhibitors,	 which	 inhibit	 viral	replication	 and	 assembly,	 although	 the	 precise	mechanism	 of	 action	 is	 unknown66.	 In	2011,	 the	 first	 two	DAAs	 that	 act	 as	NS3/4A	protease	 inhibitors	 (PI)	were	developed,	boceprevir	and	telaprevir.		In	combination	with	pegIFNα	and	ribavirin	these	triple-drug	management	could	achieve	SVR	in	more	than	70%55,	67.	Treatment	with	first-generation	PIs	 had	 substantial	 tolerability	 issues	 with	 additional	 side	 effects,	 including	 severe	anemia,	 serious	 skin	 reactions	 or	 rash,	 and	 dysgeusia,	which	 added	 to	 the	 underlying	tolerability	issues	associated	with	pegIFN	and	RBV.	Development	and	implementation	of	novel	 DAAs	 progress	 fast.	 Because	 of	 the	 considerable	 toxicity	 of	 recombinant	 IFNα,	major	 efforts	 are	 underway	 to	 develop	 IFN-free	 treatments.	 In	 2013	 two	 additional	
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DAAs	were	approved	(Sofosbuvir	und	Simeprevir).	In	2014,	multiple	IFN-free	regimens	(in	 some	 cases,	 also	RBV-free)	 became	 available	 for	 the	 treatment	 of	HCV	 genotype	1	infection	(Table	1).	The	approval	of	 these	DAAs	 further	 transformed	the	 landscape	 for	the	 treatment	 of	 HCV,	 leading	 to	 both	 improved	 efficacy	 and	 tolerability.	 IFN-free	regimens	allow	shorter	treatment	duration	with	SVR	rates	reaching	more	than	90%68,	69.	Whether	such	IFN-free	regimens	will	completely	replace	recombinant	IFNs	in	all	patient	subgroups	is	unclear,	since	many	of	the	next-generation	drugs	are	still	in	the	early	phase	of	clinical	development	and	their	overall	 	efficacy	and	safety	in	larger	patient	groups	is	not	yet	known.	Specific	concerns	include	drug–drug	interactions,	efficacy	in	patients	that	are	 also	 under	 immunosuppressive	 therapy	 (after	 organ	 or	 haematopoietic	 stem	 cell	transplantation,	 or	 in	 patients	 with	 severe	 autoimmune	 diseases)	 or	 in	 patients	 with	impaired	kidney	function15.			
	Table	1.	Currently	Available	HCV	DAAs	by	Drug	Class			
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1.2.	 Interferon	signaling	1.2.1.	Interferons	and	their	receptors	Isaacs	and	Lindenmann	identified	IFN	in	1957	during	their	studies	of	the	phenomenon	of	 viral	 interference	 characterized	 as	 the	 ability	 of	 an	 active	 or	 inactivated	 virus	 to	interfere	with	the	growth	of	an	unrelated	virus70.	IFNs	are	a	family	of	cytokines	classifed	as	type	I,	II	or	III	IFNs	based	on	the	specific	cell	surface	receptors	they	recognize.	Human	type	I	IFNs	include	12	highly	similar	members	of	the	IFNα-family,	a	single	IFN-β	as	well	as	IFNs-ε,	κ,	ω	and	ν.		Type	I	IFNs	bind	to	the	IFN-α/IFN-β	receptor	(IFNAR)	that	consists	of	the	two	subunits	IFNAR1	and	IFNAR271.	IFNAR	is	ubiquitely	expressed	on	virtually	all	cells	in	the	body.	There	is	only	one	type	II	IFN,	IFN-	γ.	It	is	produced	mainly	by	NK	and	T	cells	 in	response	to	stimulation	with	antigens	or	mitogens72,	73.	 IFNγ	binds	to	a	distinct	receptor,	the	interferon	gamma	receptor	(IFNGR)	consisting	of	the	two	subunits	IFNGR1	(previously	 called	 α	 chain)74	 and	 IFNGR2	 (previously	 called	 β	 chain	 or	 accessory	factor)75,	76.	More	recently,	a	type	III	 IFNs	have	been	described.	 	The	3	members	of	 the	type	 III	 class,	 IFNλ2,	 IFNλ3	 and	 IFNλ1(also	 known	 as	 IL28A,	 IL28B	 and	 IL29	respectively),	signal	through	the	IFN-λ	receptor	consisting	of	the	IL-10R2	chain	shared	with	the	IL-10	receptor,	and	a	unique	IFNλ	chain77,	78.	Type	I	IFNs	and	type	III	IFNs	are	produced	by	cells	 infected	with	viruses	and	by	key	sentinel	cells	of	the	innate	immune	system	such	as	macrophages	and	dendritic	 cells	 (DCs).	 Importantly,	macrophages	and	DCs	 do	 not	 have	 to	 be	 infected	 by	 viruses	 in	 order	 to	 produce	 IFNs.	 Instead,	 they	constantly	sample	the	extracellular	millieu	for	the	presence	of	foreign	materials	such	as	virus	containing	remnants	of	apoptotic	cells	and	intact	viral	particles79.	It		has		also		been		postulated		that		type	III	IFNs		might		be		induced		by	stimulation	of	cells	with	type	I	or	III	IFN,	suggesting	that	 this	class	of	cytokines	belongs	at	 the	same	time	to	the	group	IFN-stimulated	genes80.		1.2.2.	Induction	of	interferons	Cells	produce	IFNα,	IFNβ	and	IFNλ	in	response	to	infection	by	a	variety	of	viruses.	Two	important	 pathways	 that	 detect	 components	 of	 viral	 genomes	 and	 trigger	 type	 I	 and	type	 III	 IFN	expression	have	been	discovered	and	characterised	 in	recent	years.	These	include	 the	 toll-like	receptor	 (TLR)	dependent	pathway81,	82	and	 the	cytosolic	pathway	triggered	 by	 binding	 of	 viral	 RNA	 to	 the	 RNA	 helicases	 retinoic	 acid	 inducible	 gene-I	(RIG-I)	 and	melanoma	differentiation	antigen	5	 (MDA5)83.	Both	pathways	 converge	 to	
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activate	the	key	transcription	factors	NF-κB	and	the	interferon	regulatory	factor	(IRF)	3	and	7.	Activated	IRF3	and	NF-κB	bind	to	response	elements	in	the	promoters	of	type	I	and	 III	 IFN	 genes.	 All	 types	 of	 IFNs	 induce	 an	 antiviral	 state	 by	 the	 transcriptional	activation	of	hundreds	of	genes	called	interferon	stimulated	genes	(ISGs)84.	The	specific	set	of	induced	ISGs	depends	on	the	IFN	and	the	cell	type.			1.2.3.	Interferon	signaling	and	interferon	regulated	genes	IFN	receptors	connect	to	the	Jak-STAT	pathway	to	transmit	signals	from	the	cell	surface	to	 the	 nucleus	 (Figure	 7)	 85.	 All	 IFNs	 activate	 STAT1	 to	 form	 homodimers	 that	translocate	into	the	nucleus	and	bind	to	promoter	regions	containing	a	specific	gamma-activated	 sequence	 (GAS)	 to	activate	 the	 transcription	of	downstream	genes,	 so	 called	interferon	 stimulated	 genes	 (ISGs)86,	 87.	 Type	 I	 and	 III	 IFNs	 additionally	 induce	 the	heterotrimeric	transcription	factor	IFN	stimulated	gene	factor	3	(ISGF3)	that	consists	of	STAT1,	STAT2,	and	 IRF9	and	binds	 to	 IFN-stimulated	response	elements	 (ISRE)	 in	 the	promoters	of	classical	ISGs85,	88,	89,	90	(Figure	7).	The	sets	of	genes	induced	by	type	I	and	III	IFNs	in	the	same	cell	are	almost	identical,	and	partially	overlap	with	the	distinct	set	of	the	 IFN-γ-induced	gene91,	92.	Besides	 the	gene	set	 specificity	 in	a	given	cell,	 the	overall	number	 of	 regulated	 is	 different	 in	 different	 cell	 types.	 For	 instance,	 pegylated	 IFN-α	triggers	 induction	of	up	 to	300	genes	 in	 the	 liver,	but	nearly	2000	genes	 in	peripheral	blood	mononuclear	cells	(PBMCs)93.		Prolonged	 and	 intense	 IFN	 response	 can	 be	 detrimental	 and	 the	 Jak-STAT	pathway	 is	tightly	 controlled	 by	 several	 IFN-inducible	 negative	 feedback	mechanisms	 in	 order	 to	protect	the	organism	from	deleterious	consequences	of	exaggerated	immune	activation.	Important	 negative	 regulators	 include	 SOCS,	 USP18,	 PIAS	 and	 TcPTP.	 Suppressor	 of	cytokine	signalling	(SOCS)	proteins	are	rapidly	induced	by	activated	STATs	and	provide	an	 early	 negative	 feedback	 loop94,	 95,	 96.	 Ubiquitin-specific	 peptidase	 18	 (USP18,	 also	designated	 UBP43)	 is	 another	 important	 negative	 regulator	 in	 type	 I	 IFN	 signaling97.	USP18	 is	 a	 key	mediator	 of	 the	 refractoriness	 of	 liver	 cells	 to	 continuous	 stimulation	with	 IFN-α65.	 USP18	 is	 not	 induced	 by	 IFN-γ,	 and	 does	 not	 inhibit	 IFN-γ	 or	 IFN-λ	signalling64.			Genes	 induced	 by	 IFN	 stimulation	 contribute	 to	 the	 establishment	 of	 the	 so-called	antiviral	 state.	 IFN	 stimulation	 typically	 leads	 to	 up-	 and	 down-regulation	 of	 several	hundred	genes,	many	of	which	are	regulated	in	a	cell-type	specific	manner.		Only	a	small	
	 22	
number	of	the	IFN-induced	antiviral	effectors	have	been	studied	in	detail	to	reveal	their	mode	of	action	in	inhibiting	viral	infections.		To	date,	four	main	effector	pathways	of	the	IFN-mediated	antiviral	response	have	been	described.	These	include	pathways	triggered	by	the	Mx	GTPase,	the	ISG15	ubiquitin-like	protein,	the	OAS-RNaseL	system	and	protein	kinase	R84.			
	
Figure	7:	IFN	Signaling	through	the	Jak-STAT	Pathway							 	
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1.3.	Innate	and	adoptive	immune	response	in	Hepatitis	C	infection		1.3.1.	Innate	and	adaptive	immune	response	in	acute	HCV	(AHC)	infection	The	 acute	 phase	 of	 HCV	 infection	 is	 divided	 in	 an	 early	 acute	 phase	 prior	 to	 the	activation	 and	 recruitment	 of	HCV	 specific	 T	 cells	 in	 the	 liver,	 and	 a	 late	 acute	 phase,	characterized	by	 the	 adaptive	 immune	 response	 (Figure	8).	 Innate	 immune	 responses	are	 the	 first	 line	 of	 defense	 against	 pathogens	 including	 viral	 infections.	 IFNs	 are	 the	central	 cytokine	 mediators	 responsible	 for	 the	 induction	 of	 a	 innate	 antiviral	 state	within	cells	and	also	for	the	activation	and	regulation	of	the	cellular	components	of	the	innate	immune	system	such	as	natural	killer	(NK)	cells98.	However,	little	is	known	about	the	 early	 induction	 of	 innate	 immune	 responses	 in	 HCV	 infection	 because	 the	 acute	phase	 of	 HCV	 infection	 is	 only	 infrequently	 diagnosed	 due	 to	 the	 very	 mild	 and	unspecific	clinical	manifestation.	Furthermore,	the	few	prospective	studies	of	acute	HCV	infection	 that	were	done	with	health-care	workers	 after	 accidental	needle	 stick	 injury	typically	focused	on	the	analysis	of	the	adaptive	immune	response	to	HCV	infection.	Our	current	 understanding	 of	 the	 early	 hepatic	 events	 during	 HCV	 infection	 derives	 from	studies	 using	 serial	 liver	 biopsy	 and	 blood	 samples	 obtained	 from	 experimentally	infected	 chimpanzees99,	 100,	 101,	 102.	 High	 HCV	 viral	 titers	 have	 been	 observed	 in	chimpanzee	 serum	 and	 liver	 already	within	 days	 after	 inoculation.	 After	 a	 very	 rapid	increase	in	the	first	2	weeks	after	an	infection,	HCV	viral	loads	remain	stable	for	several	weeks,	until	 the	emergence	of	a	cellular	 immune	response	 in	 the	 liver.	Transcriptomic	analysis	of	the	liver	biopsy	derived	RNA	revealed	induction	of	type	I	IFN	response	in	the	early	 acute	 phase	 of	 infection.	 The	 extent	 and	 duration	 of	 the	 ISG	 induction	 was	positively	 correlated	 with	 the	 viral	 load.	 However,	 despite	 this	 apparent	 and	 strong	innate	 immune	 response	 during	 the	 acute	 phase	 of	HCV	 infection,	 the	 infection	 is	 not	cleared	in	most	cases.	Although	there	is	evidence	that	HCV	could	trigger	IFN	production	in	the	cells	it	infects,	this	has	so	far	not	been	proven	and	the	cellular	source	and	type	of	IFN	that	triggers	the	massive	ISG	induction	during	acute	HCV	infection	still	remains	to	be	identified.	 	While	several	reports	suggest	that	HCV	triggers	type	III	IFN	induction	in	primary	 human	 PHH	 it	 infects42,	 103,	 104,	 other	 groups	 reported	 that	 plasmacytoid	dendritic	 cells,	 stimulated	 by	 cell-cell	 contact	with	 infected	 hepatocytes,	might	 be	 the	source	of	primarily	type	I	IFNs105.	More	recent	studies	detected	up-regulation	of	mRNA	of	type	III	(but	not	type	I)	IFNs	in	liver	biopsies	of	chimpanzees	and	an	increase	of	type	III	IFN	protein,	primarily	IFN-λ1	(IL29),	in	the	serum	of	chimpanzees.	
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In	contrast	to	the	innate	immune	responses	that	are	induced	within	days	after	infection,	adaptive	immune	responses,	that	correspond	to	the	late	acute	phase	become	detectable,	for	 reasons	not	 yet	 clearly	understood,	 only	 after	6–8	weeks101,	106,	107	 (Figure	8).	This	phase	 lasts	 4–10	weeks	 and	 is	 clinically	 characterized	 by	 elevated	 transaminases	 and	sometimes	 icterus,	 and	 leads	 to	 clearance	 of	 the	 infection	 in	 about	 30%	 of	 infected	individuals.	 There	 is	 general	 consensus	 from	 a	 number	 of	 immunological	 studies	 that	HCV	 elimination	 requires	 sustained,	 strong	 and	 multispecific	 HCV-specific	 CD4+	 and	CD8+	T	cell	responses79.	The	combination	of	non-cytolytic	inhibition	of	virus	replication	and	 production	 reduces	 viral	 spread	 while	 the	 adaptive	 response	 eliminates	 the	 still	infected	cells108.		
   		
Figure	8:	Natural	course	of	HCV	Infection				1.3.2.	Innate	immune	response	during	chronic	HCV	infection		The	 chronic	 phase	 of	 HCV	 infection	 is	 primarily	 characterized	 by	 a	 largely	 ineffective	cellular	 immune	 response	probably	 caused	by	 a	 combination	of	T	 cell	 exhaustion	 and	emergence	of	viral	escape	mutants.	Even	though	the	IFN	system	is	still	activated	in	the	liver,	it	is	not	is	not	sufficient	to	clear	the	virus	(reviewed	in79).	In	humans	who	develop	chronic	infection,	ISG	induction	varies	considerably	between	individuals.	In	about	half	of	Caucasian	patients,	hundreds	of	type	I	or	III	ISGs	are	constantly	expressed	at	high	levels	in	 the	 liver,	whereas	 the	other	half	 has	no	detectable	 induction	of	 the	 innate	 immune	
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system109.	Apart	from	a	strong	association	of	allelic	variants	near	the	IFN-λ4	gene	with	ISG	induction,	little	is	known	about	the	factors	that	determine	the	activation	level	of	the	IFN	system.110,	111,	112.		HCV	persists	for	decades	despite	the	expression	of	hundreds	of	ISGs93.	Furthermore,	in	contrast	to	what	is	seen	during	AHC,	there	is	no	significant	correlation	between	serum	or	 intrahepatic	 viral	 loads	 with	 ISG	 expression	 levels109.	 The	 interplay	 between	 viral	replication	 levels	 and	 ISG	 induction	 in	 the	 liver	 is	 still	 unknown,	 Nevertheless,	intrahepatic	 ISG	 expression	 seems	 to	 be	 maximal	 in,	 but	 not	 restricted	 to	 the	 HCV	infected	cell	as	determined	by	simultaneous	HCV	RNA	and	ISG	mRNA	by	fluorescent	in	situ	hybridization	 suggesting	 that	HCV	 itself	 is	 the	main	driver	of	 the	observed	 innate	response109.			1.3.3.	 Non-response	 to	 PegIFN-α	 in	 CHC	 patients	 with	 an	 activated	endogenous	IFN	system	in	the	liver	It	is	known	that	patients	with	an	activated	endogenous	IFN	system	are	poor	responders	to	IFN-α	based	therapies93,	113,	114.	Analysis	of	paired	liver	biopsies	obtained	before	and	4	h	 after	 the	 first	 injection	 of	 PegIFN-α2	 revealed	 that	 patients	 with	 an	 activated	endogenous	 IFN	 system	had	hundreds	of	 ISGs	 expressed	at	high	 levels	 already	before	treatment.	 Staining	of	 these	biopsies	 for	 the	phosphorylated	 form	of	 STAT1	 showed	a	faint	staining	in	nuclei	of	hepatocytes	in	pre-treatment	biopsies,	and	no	further	increase	of	phospho-STAT1	signals	4	h	after	PegIFN-α	injections.	In	contrast,	no	phospho-STAT1	signals	 were	 detected	 in	 pre-treatment	 biopsies	 of	 patients	 without	 activated	endogenous	IFN	system,	but	PegIFN-α	injections	 induced	a	very	prominent	and	strong	activation	 and	nuclear	 translocation	within	4	h93.	 The	 reason	 for	 the	 refractoriness	 of	IFN-α	induced	Jak-STAT	signaling	is	not	entirely	clear,	but	there	is	evidence	that	USP18	is	 an	 important	 factor115.	 USP18	 was	 strongly	 expressed	 in	 a	 large	 number	 of	hepatocytes	 in	 liver	 biopsies	 from	patients	with	 CHC	 and	 a	 pre-activated	 endogenous	IFN	system	115.						
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1.3.3.	Genetic	variations	and	treatment	outcome	Genome	wide	association	studies	revealed	that	genetic	variants	near	the	interleukin	28B	(IL28B)	 strongly	 associated	 not	 only	with	 spontaneous	 clearance	 of	 the	 infection,	 but	also	 with	 the	 success	 rate	 of	 PegIFN-α/ribavirin	 antiviral	 treatment	 116,	117,	118,	119,	120.	IL28B	 corresponds	 to	 IFN	 λ3,	 further	 analysis	 however	 revealed	 that	 an	 additional	polymorphism	 located	 within	 IFNl4	 gene	 has	 even	 stronger	 predictive	 value121.	 The	INFλ4	 gene	 harbors	 several	 genetic	 variants	 in	 human	 populations,	 including	 a	frameshift	mutation	that	abrogates	 the	production	of	 the	 INFλ4	protein.	Paradoxically,	the	 INFλ4-producing	 genotype	 is	 associated	 with	 poor	 response	 to	 PegIFN-α/	ribavirin110,	116,	120.	The	variability	within	 the	 IFNλs	seems	to	result	primarily	 from	two	polymorphisms	 (rs368234815	 and	 rs117648444)	 that	 determine	 three	 haplotypes,	each	associated	with	a	different	pattern	of	IFNλ4	expression	(Figure	9)110.	The	first,	TT	G	haplotype	is	predicted	not	to	produce	IFNλ4	and	patients	have	low	ISG	expression	in	the	liver	and,	surprisingly,	a	higher	incidence	of	spontaneous	clearance.	Likewise,	they	show	a	better	response	rate	to	IFN-based	treatment.	The	second,	ΔG	G	haplotype	is	predicted	to	express	the	IFNλ4-P70	variant	and	patients	produce	important	amounts	of	ISG	in	the	liver	 and	 have	 a	 low	 ability	 to	 clear	 HCV.	 The	 third,	 ΔG	 A	 haplotype	 is	 predicted	 to	express	the	IFNλ4-S70	variant	and	patients	have	an	intermediate	ability	to	clear	HCV.		It	is	presently	not	known	why	the	activation	of	the	endogenous	IFN	system	in	the	liver	in	patients	 with	 the	 IFNλ4-producing	 genotype	 is	 ineffective	 against	 HCV,	 whereas	pegIFNα-induced	ISG	expression	results	in	viral	eradication	in	so	many	patients.		
		
Figure	9:	Genetic	polymorphisms	in	the	IFNλ4	gene	determine	IFN	stimulated	gene	
induction	and	viral	clearance.	The	rs368234815	and	rs117648444	polymorphisms	
determine	3	haplotypes	that	predict	a	different	expression	of	IFNλ4	(none,	70P	variant	
and	70S	variant).		 	
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2. Aims	of	the	MD-PhD	project		The	overall	aim	of	the	project	was	to	investigate	the	host	response	to	hepatitis	C	virus	(HCV)	infection	in	the	human	liver	by	a	systematic	analysis	of	the	transcriptome	using	liver	biopsies	of	patients	with	HCV	infection	and	of	controls.		The	analysis	focused	on	4	aspects:		 1. The	cell	intrinsic	adaptations	in	HCV	infected	hepatocytes.		2. The	 induction	 of	 IFN	 stimulated	 genes	 (ISGs)	 and	 long	 noncoding	 RNAs	 in	 the	liver	of	patients	with	chronic	hepatitis	C	(CHC).		3. The	induction	of	ISGs	and	long	noncoding	RNAs	in	patients	treated	with	pegIFNα	and	 comparison	of	 these	data	 to	RNA	 seq	data	 from	patients	with	 an	 activated	endogenous	IFN	system.		4. The	contribution	of	miRNAs	to	ISG	expression	induced	by	pegIFNα.		In	the	first	part	of	our	study	we	aimed	to	disentangle	the	direct	and	indirect	effects	of	HCV	infection	on	the	cellular	gene	expression	profile.	We	therefore	carefully	selected	a	set	 of	 biopsies	 without	 detectable	 immune	 response	 and	 compared	 high-throughput	RNA	sequencing	profiles	of	these	biopsies	with	biopsies	from	non-infected	patients.			In	 the	 second	 part	 of	 the	 study,	 RNA	 seq	 data	 from	 liver	 biopsies	 of	 patients	 with	 a	strong	induction	of	the	endogenous	IFN	system	were	compared	to	controls.		In	the	third	part,	a	number	of	patients	were	biopsied	before	and	at	different	time	points	during	the	week	after	the	first	injection	of	pegIFNα.	This	study	design	allowed	a	unique	insight	 into	 pharmacodynamics	 effects	 of	 pegIFNα	 in	 the	 human	 liver.	 The	 data	were	then	 compared	 to	 the	 RNA	 seq	 data	 from	 patients	 with	 a	 strong	 activation	 of	 the	endogenous	IFN	system	with	the	aim	to	identify	the	differences	between	exogenous	and	endogenous	ISG	induction	responsible	for	viral	eradication	by	pegIFNα	treatments.			In	the	fourth	part,	we	addressed	the	role	of	miRNAs	in	pegIFNα	induced	gene	regulation	in	the	liver.		 	
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Abstract	Hepatitis	C	virus	(HCV)	is	widely	used	to	investigate	host-virus	interactions.	Cellular	responses	to	HCV	infection	have	been	extensively	studied	in	vitro.	However,	in	human	liver,	interferon	(IFN)	stimulated	gene	expression	can	mask	direct	transcriptional	responses	to	infection.	To	better	characterize	the	direct	effects	of	HCV	infection	in	vivo,	we	analyze	the	transcriptomes	of	HCV-infected	patients	lacking	an	activated	endogenous	IFN	system.	We	show	that	expression	changes	observed	in	these	patients	predominantly	reflect	immune	cell	infiltrates	rather	than	cell-intrinsic	pathways.	We	also	investigate	the	transcriptomes	of	patients	with	endogenous	IFN	activation,	which	paradoxically	cannot	eradicate	viral	infection.	We	find	that	most	IFN-stimulated	genes	are	induced	by	both	recombinant	IFN	therapy	and	the	endogenous	IFN	system,	but	with	lower	induction	levels	in	the	latter,	indicating	that	the	innate	immune	response	in	chronic	hepatitis	C	is	too	weak	to	clear	the	virus.	We	show	that	coding	and	non-coding	transcripts	have	different	expression	dynamics	following	IFN	treatment.	Several	microRNA	precursors,	including	miR-122,	are	significantly	down-regulated	in	response	to	IFN	treatment,	suggesting	a	new	mechanism	for	IFN-induced	expression	fine-tuning.					
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Introduction	Hepatitis	C	virus	(HCV)	infections	are	a	major	cause	of	liver-related	morbidity	and	mortality.	An	estimated	160	million	persons	are	chronically	infected	worldwide	and	are	at	risk	to	develop	liver	cirrhosis	and	hepatocellular	carcinoma(Lavanchy,	2011).	Because	of	their	substantial	impact	on	human	health,	HCV	infections	have	been	extensively	studied.	HCV	is	now	one	of	the	most	widely	used	model	systems	to	investigate	host-virus	interactions(Colpitts	et	al,	2015).	HCV	is	transmitted	through	blood	and	infects	and	replicates	in	hepatocytes.	Due	to	the	lack	of	a	small	animal	model	and	of	the	difficulties	inherent	to	working	with	human	samples,	HCV-host	cell	interactions	have	been	mainly	studied	in	a	cell	culture	system,	specifically	in	Huh7-derived	hepatoma	cells	infected	with	the	JFH1	isolate	of	the	virus(Colpitts	et	al,	2015;	Lindenbach	et	al,	2005;	Wakita	et	al,	2005;	Walters	et	al,	2009;	Zhong	et	al,	2005).	Experiments	in	this	in	vitro	system	have	identified	a	large	number	of	host	factors	that	are	required	for	viral	replication	or	that	have	antiviral	properties(Colpitts	et	al,	2015).	This	experimental	system	also	brought	important	insights	into	the	virus-host	interactions	that	may	contribute	to	pathogenesis,	for	example	revealing	cell	cycle	perturbations	in	HCV-infected	cells(Walters	et	al,	2009).	However,	few	of	these	findings	have	been	evaluated	in	the	human	liver.			Studying	HCV	infections	in	vivo	presents	important	challenges.		An	intrinsic	difficulty	comes	from	the	immune	response,	which	is	a	strong	confounding	factor	in	analyses	of	human	liver	biopsies.	Gene	expression	differences	between	HCV-infected	and	un-infected	livers	are	the	result	of	direct	HCV-induced	cell-autonomous	adaptive	responses	in	infected	cells	and	of	more	global	changes	that	result	from	the	immune	response	in	the	liver.	The	chronic	phase	of	HCV	infections	is	characterized	by	a	largely	ineffective	cellular	immune	response	combined	with	a	highly	variable	interferon	lambda	(IFNl)	mediated	innate	immune	response(Heim	&	Thimme,	2014).	A	significant	proportion	of	patients	are	characterized	by	an	endogenous	activation	of	the	interferon	(IFN)	system,	in	which	hundreds	of	classical	IFN-stimulated	genes	(ISGs)	are	strongly	induced(Heim	&	Thimme,	2014).	The	presence	of	the	endogenous	IFN	system	activation	can	mask	more	subtle	changes	that	occur	as	a	direct	consequence	of	viral	infection	and	replication	in	HCV-infected	cells.	The	confounding	effect	of	the	immune	answer	is	aggravated	by	the	fact	that	the	percentage	of	HCV-infected	hepatocytes	rarely	exceeds	50%	and	often	is	
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below	20%,	whereas	ISG	expression	can	be	observed	in	up	to	95%	of	cells(Wieland	et	al,	2014).	To	better	understand	the	molecular	consequences	of	HCV	infection	in	vivo,	it	is	thus	important	to	disentangle	the	direct	cellular	response	to	viral	infections	from	the	transcriptional	signature	of	the	immune	response,	and	in	particular	of	the	endogenous	IFN	system	activation.			The	endogenous	activity	of	the	IFN	system	is	also	highly	relevant	for	therapeutic	choice	in	chronic	hepatitis	C	(CHC).	Until	the	recent	introduction	of	direct	antiviral	drugs	for	the	treatment	of	CHC,	recombinant	pegylated	IFN	alpha	2	(pegIFNa)	had	been	an	essential	component	of	the	standard	of	care	for	CHC	for	over	25	years,	and	it	is	still	used	in	many	parts	of	the	world.	Treatment	with	pegIFNa	and	ribavirin	achieved	cure	rates	between	30-80%,	depending	on	the	viral	genotype,	pretreatment	patient	history	and	stage	of	liver	fibrosis(Heim,	2013).	The	success	of	the	treatment	is	also	highly	dependent	on	the	genetic	background	of	the	patients.	Genome-wide	association	studies	revealed	significant	associations	between	polymorphisms	in	the	IFNL4	gene	and	response	to	pegIFNa/ribavirin(Bibert	et	al,	2013;	Prokunina-Olsson	et	al,	2013;	Terczynska-Dyla	et	al,	2014).	The	recently	discovered	IFNL4	protein	has	strong	antiviral	properties	and	stimulates	ISG	production	through	binding	to	the	IFN	lambda	receptor(Hamming	et	al,	2013;	Prokunina-Olsson	et	al,	2013).	The	IFNL4	gene	harbors	several	genetic	variants	in	human	populations,	including	a	frameshift	mutation	that	abrogates	the	production	of	the	IFNL4	protein(Terczynska-Dyla	et	al,	2014).	Paradoxically,	the	IFNL4-producing	genotype	is	associated	with	poor	response	to	pegIFNa/ribavirin,	whereas	mutated	alleles	coding	for	an	IFNL4	variant	with	strongly	reduced	biological	activity	or	even	a	complete	loss	of	function	are	associated	with	very	good	spontaneous	and	treatment-induced	resolution	rates(Terczynska-Dyla	et	al,	2014).	These	observations	are	consistent	with	earlier	findings	that	patients	who	have	a	strong	endogenous	induction	of	ISGs	during	the	chronic	phase	of	HCV	infection	do	not	respond	to	therapeutically	injected	pegIFNa(Asselah	et	al,	2008;	Chen	et	al,	2005;	Sarasin-Filipowicz	et	al,	2008).	It	is	presently	not	known	why	the	activation	of	the	endogenous	IFN	system	in	the	liver	in	patients	with	the	IFNL4-producing	genotype	is	ineffective	against	HCV,	whereas	pegIFNa-induced	ISG	expression	results	in	viral	eradication	in	so	many	patients.			In	this	study,	we	aimed	to	disentangle	the	direct	and	indirect	effects	of	HCV	infection	on	gene	expression	patterns,	by	performing	a	detailed	characterization	of	the	gene	
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expression	changes	associated	with	HCV	infection,	endogenous	IFN	system	activation	and	pegIFNa	treatment	in	the	human	liver.	With	this	objective,	we	generated	and	analyzed	high-throughput	transcriptome	sequencing	profiles	from	liver	biopsies	derived	from	different	categories	of	HCV-infected	and	non-infected	patients,	prior	to	and	during	treatment.	First,	to	unveil	HCV-induced	cell-autonomous	effects	and	to	separate	them	from	IFN-induced	changes	in	the	transcriptome,	we	selected	liver	biopsies	from	CHC	patients	without	hepatic	ISG	induction,	and	compared	them	with	un-infected	control	biopsies.	Second,	we	examined	the	transcriptomic	changes	associated	with	the	endogenous	activation	of	the	IFN	system	in	a	subset	of	CHC	patients.	Finally,	we	analyzed	the	gene	expression	changes	resulting	from	pegIFNa/ribavirin	treatment,	by	comparing	transcriptome	data	from	liver	biopsies	obtained	before	treatment	and	at	different	time	points	during	the	first	week	of	therapy.	We	found	that	the	transcriptional	profiles	associated	with	endogenous	IFN	activation	and	with	pegIFNa/ribavirin	treatment	share	a	core	set	of	IFN-stimulated	genes,	although	quantitative	differences	can	be	found	in	gene	activation	levels.				Throughout	our	study,	we	investigated	the	differential	expression	patterns	of	both	protein-coding	genes	and	non-coding	RNAs,	aiming	to	clarify	the	regulatory	mechanisms	underlying	the	transcriptomic	changes	induced	by	HCV	infection	and	pegIFNa	treatment.	In	particular,	we	evaluated	the	roles	of	microRNAs	(miRNAs)	in	the	regulation	of	the	hepatocellular	and	immunological	host	response	to	HCV	infection.	Interestingly,	we	found	that	the	precursor	transcripts	of	several	miRNAs	(including	miR-122,	which	is	required	for	HCV	replication(Jopling	et	al,	2005))	are	down-regulated	following	pegIFNa	treatment	in	the	human	liver.	Consistently,	we	observe	a	subtle	up-regulation	of	the	corresponding	miRNA	target	genes,	indicating	that	the	expression	changes	observed	for	the	precursor	transcripts	are	reflected	in	the	mature	miRNA	levels.	Although	these	findings	warrant	further	validation,	we	propose	that	the	down-regulation	of	miRNA	precursors,	in	particular	of	miR-122,	may	contribute	to	efficiency	of	HCV	clearance	by	pegIFNa/ribavirin	treatment.						 	
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Results	
	
Expression	patterns	of	interferon-stimulated	genes	define	two	classes	of	CHC	
patients		Previous	studies	focusing	on	the	response	to	interferon	(IFN)	treatment	in	chronic	hepatitis	C	(CHC)	revealed	the	existence	of	a	subset	of	patients	with	high	endogenous	levels	of	interferon-stimulated	genes	(ISGs)(Sarasin-Filipowicz	et	al,	2008).	This	distinction	between	two	categories	of	CHC	patients	is	highly	relevant	when	seeking	to	determine	the	molecular	consequences	of	HCV	infection	in	the	human	liver,	which	otherwise	can	be	confounded	by	the	endogenous	activation	of	the	IFN	system.	We	thus	analyzed	the	expression	levels	of	ISGs	in	the	examined	CHC	patients.	To	do	this,	we	mined	a	previously	published	dataset	of	ISGs(Dill	et	al,	2014)	and	extracted	a	set	of	genes	that	are	strongly	up-regulated	in	the	human	liver	upon	pegIFNa	treatment,	requiring	a	minimum	expression	fold	change	of	2	across	all	studied	time	points.	We	thus	obtained	a	set	of	20	strong	ISGs	and	we	assessed	their	expression	levels	in	28	liver	biopsies	(including	control	non-infected	samples,	termed	hereafter	non-CHC)	in	our	dataset	(Fig.	1a,	Supplementary	Table	1).			A	hierarchical	clustering	approach	applied	on	centered	and	scaled	gene	expression	levels	confirmed	the	existence	of	two	main	groups	of	patients	(Fig.	1a).	The	first	group,	characterized	by	overall	low	ISG	transcript	levels,	comprised	21	samples,	including	all	6	non-CHC	liver	biopsies	and	15	of	the	CHC	samples.	Importantly,	no	clear	distinction	was	found	between	the	non-CHC	and	the	CHC	samples	in	this	group.	The	second	group,	consisting	of	7	CHC	samples,	displayed	higher	expression	levels	across	the	20	analyzed	ISGs	(Fig.	1a).	Importantly,	we	note	that	this	separation	between	two	groups	of	patients	cannot	be	explained	by	the	HCV	genotype	carried	by	the	CHC	patients,	as	all	four	genotypes	were	found	in	the	7	patients	with	high	ISG	levels	(Fig.	1a).	Similarly,	analysis	of	the	inflammation	and	fibrosis	METAVIR	scores(Bedossa	&	Poynard,	1996)	and	of	the	HCV	viral	load	indicated	that	these	factors	cannot	explain	the	patient	grouping	(Fig.	1a,b).	To	verify	that	the	clustering	of	CHC	samples	was	not	dependent	on	the	set	of	genes	used	as	markers,	we	performed	a	principal	component	analysis	on	360	genes	associated	with	Gene	Ontology	(GO)	categories	related	to	response	to	interferon	(Methods).	This	
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analysis	confirmed	that	our	sample	sub-classification	is	robust	with	respect	to	the	choice	of	the	ISG	input	dataset	(Supplementary	Fig.	1).				
Gene	expression	changes	induced	by	HCV	in	the	absence	of	the	endogenous	IFN	
system	activation		We	first	aimed	to	investigate	the	gene	expression	changes	induced	by	HCV	infection,	without	the	confounding	effect	of	the	activation	of	the	endogenous	IFN	system,	and	without	the	confounding	effects	of	strong	inflammation	or	fibrosis.	We	thus	compared	gene	expression	levels	between	6	non-CHC	and	a	subset	of	7	CHC	low	ISG	samples	with	METAVIR	scores	≤	A2F3,	using	the	Wald	test	for	differential	expression	implemented	in	DESeq2(Love	et	al,	2014)	and	a	sample	randomization	procedure	to	minimize	outlier	effects	(Methods).	We	identified	179	robustly	differentially	expressed	protein-coding	genes,	at	a	false	discovery	rate	(FDR)	threshold	of	10%	and	requiring	an	absolute	fold	change	above	1.5	(Fig.	2a,	Supplementary	Table	2).	With	the	same	parameters,	we	discovered	14	long	non-coding	RNAs	(Methods)	and	43	genes	with	unclear	classification	(including	pseudogenes	and	other	classes	of	non-coding	RNAs,	Methods)	that	were	robustly	differentially	expressed	between	the	two	sample	categories	(Fig.	2a).	Most	differentially	expressed	protein-coding	genes	were	up-regulated	in	the	CHC	low	ISG	patients	compared	to	controls,	reaching	a	maximum	fold	change	of	8.			We	next	examined	the	protein-coding	genes	with	the	highest	absolute	fold	change	between	the	two	groups	of	samples	(Fig.	2b).	The	strongest	up-regulated	genes	included	genes	typically	expressed	in	immune	system	cells,	including	IGHG1,	IGHG3,	CD27,	CD5,	etc.	(Fig.	2b).	Genes	specifically	associated	with	defense	against	viral	infections,	such	as	
OASL,	were	also	strongly	up-regulated	(Fig.	2b).	A	gene	ontology	(GO)	analysis	for	up-regulated	protein-coding	genes	revealed	strong	enrichment	for	biological	processes	related	to	lymphocyte	and	leukocyte	activation,	including	more	specific	terms	like	T-cell	and	B-cell	activation	(Supplementary	Table	3).	In	contrast,	down-regulated	genes	were	enriched	for	processes	related	to	the	protein	activation	cascade,	response	to	stimulus	or	complement	activation,	although	these	patterns	were	driven	by	only	a	few	genes	(Supplementary	Table	3).			
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We	then	analyzed	the	expression	patterns	of	these	genes	in	the	broad	collection	of	human	tissue	transcriptomes	of	the	GTEx	consortium(Mele	et	al,	2015).	In	agreement	with	the	GO	association	with	immune	system	cells,	up-regulated	genes	were	most	highly	expressed	in	the	whole	blood,	in	the	lymphocytes	or	in	the	spleen	(Fig.	2c),	while	down-regulated	genes	generally	reached	maximum	expression	in	the	liver	or	in	adipose	tissue	(Fig.	2c).	Moreover,	an	analysis	of	the	transcription	factor	binding	motifs	over-represented	in	the	promoters	of	the	genes	up-regulated	in	low	ISG	patients	revealed	the	presence	of	several	transcription	factors	associated	with	immune	system	cells,	including	members	of	the	ETS	family,	the	E2A,	NFKB	and	SPIB	transcription	factors	(Supplementary	Fig.	2a).	No	motif	enrichment	was	found	for	genes	down-regulated	in	CHC	low	ISG	samples.	Taken	together,	these	results	indicate	that	the	gene	expression	changes	observed	in	this	class	of	HCV-infected	patients	largely	result	from	the	recruitment	of	immune	system	cells	into	the	liver.			To	further	explore	the	regulatory	mechanisms	driving	differential	gene	expression	patterns,	we	examined	the	behavior	of	microRNA	(miRNA)	target	genes.	Experiments	in	Huh7	hepatocellular	carcinoma	cells	recently	showed	that	HCV	functionally	sequesters	miR-122,	thus	reducing	its	binding	to	endogenous	target	genes	and	leading	to	their	up-regulation(Luna	et	al,	2015).	To	assess	whether	this	observation	also	holds	in	vivo,	we	analyzed	the	expression	fold	change	of	predicted	miRNA	targets	in	CHC	low	ISG	samples	compared	to	non-CHC	samples	(Fig.	2d).	We	analyzed	a	set	of	microRNAs	expressed	in	normal	and/or	HCV-infected	human	livers(Hou	et	al,	2011)	and	a	set	of	evolutionarily	conserved	miRNA	targets	predicted	computationally	with	TargetScan(Agarwal	et	al,	2015)	(Supplementary	Table	4,	Methods).	We	found	that	miR-122	targets	had	significantly	higher	fold	changes	(median	0.045)	than	targets	of	other	expressed	miRNAs	(median	-0.015,	Wilcoxon	rank	sum	test,	p-value	0.018)	and	than	genes	not	targeted	by	this	set	of	liver	miRNAs	(median	-0.14,	Wilcoxon	rank	sum	test,	p-value	<	1e-10,	Fig.	2d).	These	observations	are	compatible	with	the	reported	subtle	de-repression	of	miR-122	target	genes	in	the	presence	of	HCV	infection(Luna	et	al,	2015).	However,	we	also	found	that	miR-122	targets	have	comparable	expression	fold	changes	with	the	targets	of	other	highly	expressed	miRNAs,	such	as	miR-192,	let-7	or	miR-199	(Fig.	2d).	Similar	conclusions	were	reached	when	analyzing	a	set	of	miRNA	targets	identified	in	Huh7	cells	using	high-throughput	sequencing	of	RNA	isolated	by	crosslinking	immunoprecipitation(Luna	et	al,	2015)	(Supplementary	Fig.	2b,	
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Supplementary	Table	4).	Overall,	the	fold	expression	change	was	positively	correlated	with	the	number	of	distinct	miRNA	families	that	are	predicted	to	target	each	gene	(Supplementary	Fig.	2c).	This	observation	cannot	be	simply	explained	by	the	previously	reported	sequestration	of	miR-122	by	HCV,	but	may	reflect	the	expression	or	functional	characteristics	of	genes	targeted	by	multiple	miRNA	families.	Our	results	thus	reveal	a	potential	confounding	factor	in	the	up-regulation	of	miR-122	targets	following	HCV	infection.			
Gene	expression	patterns	associated	with	endogenous	IFN	system	activation		
	We	next	investigated	the	gene	expression	changes	driven	by	the	combined	effect	of	HCV	infection	and	endogenous	IFN	system	activation.	To	do	this,	we	contrasted	gene	expression	levels	between	non-CHC	and	CHC	high	ISG	samples	(Methods).	Using	the	same	parameters	as	above,	we	observed	numerous	differentially	expressed	genes	in	the	high	ISG	patients,	including	503	protein-coding	genes,	80	candidate	long	non-coding	RNAs	and	125	other	genes	(Fig.	3a,	Supplementary	Table	2).	The	observed	expression	fold	changes	and	significance	levels	spanned	a	wider	range	than	for	the	comparison	between	non-CHC	and	CHC	low	ISG	patients	(Fig.	2a	and	3a).	As	expected,	the	most	highly	up-regulated	protein-coding	genes	were	known	ISGs,	including	LAMP3,	IFI27	and	
RSAD2	(Fig.	3b).	The	up-regulated	long	non-coding	RNAs	included	a	previously	described	interferon-inducible	transcript,	NRIR(Kambara	et	al,	2014)	(Fig.	3c).			Gene	ontology	analyses	showed	a	strong	enrichment	for	genes	involved	in	immune	system	processes,	in	particular	response	to	virus	and	type	I	interferon	signaling	pathway	(Supplementary	Table	3).	Interestingly,	the	GO	categories	found	to	be	enriched	among	the	genes	up-regulated	in	CHC	low	ISG	patients	were	generally	also	over-represented	in	this	second	comparison,	although	the	enrichment	was	much	weaker	than	the	one	observed	for	the	interferon	pathway	(Supplementary	Table	3).	In	agreement	with	these	observations,	we	found	that	interferon-stimulated	response	element	(ISRE)	motifs	and	IFN-regulatory	factors	(IRF)	motifs	were	strongly	over-represented	in	the	promoters	of	the	genes	up-regulated	in	CHC	high	ISG	samples	(Supplementary	Fig.	3).	However,	we	also	observed	a	significant	enrichment	for	NFKB	and	ERG	motifs	(Supplementary	Fig.	3),	indicating	the	presence	of	immune	cells	in	these	high	ISG	
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samples.	The	promoters	of	down-regulated	genes	were	enriched	in	binding	sites	for	two	liver-specific	transcription	factors,	HNF4a	and	HNF1,	indicating	that	most	down-regulated	genes	are	hepatocyte-specific	genes	(Supplementary	Fig.	3).	As	in	the	comparison	between	non-CHC	and	CHC	low	ISG	samples	(see	above),	we	found	no	evidence	for	a	specific	de-repression	of	miR-122	target	genes	(Fig.	3d).			Overall,	genes	differentially	expressed	between	CHC	low	ISG	and	non-CHC	samples	were	recovered	in	the	comparison	between	CHC	high	ISG	and	non-CHC	samples	(Fig.	4).	Specifically,	we	found	that	114	(64%)	of	the	179	protein-coding	genes	that	differed	(up	or	down)	between	CHC	low	ISG	and	non-CHC	samples	were	also	differentially	expressed	between	CHC	high	ISG	and	non-CHC	samples	(Fig.	4a).	The	remaining	genes	that	were	only	differentially	expressed	in	low	ISG	compared	to	non-CHC	patients	generally	displayed	consistent	fold	changes	in	both	comparisons,	but	did	not	pass	the	FDR	threshold	when	comparing	CHC	high	ISG	and	non-CHC	samples	(Fig.	4b-d).	In	contrast,	most	of	the	genes	that	were	uniquely	up-regulated	or	down-regulated	in	CHC	high	ISG	patients	compared	to	controls	had	only	weak	expression	changes	in	the	comparison	between	CHC	low	ISG	and	control	samples	(Fig.	4b,	e,	f).	These	observations	are	consistent	with	the	presence	of	a	unique	expression	signature	associated	with	the	group	of	high	ISG	patients	(Fig.	1a).	To	further	define	this	expression	signature,	we	directly	compared	the	two	groups	of	CHC	samples	(Supplementary	Fig.	4,	Supplementary	Table	2).	We	found	numerous	genes	with	significant	expression	changes,	including	176	protein-coding	genes	and	21	lncRNA	candidates	(Supplementary	Fig.	4).	As	expected,	we	observed	a	strong	enrichment	for	biological	processes	associated	with	defense	response	to	virus	and	type	I	interferon	signaling	pathway	among	the	genes	up-regulated	in	high	ISG	(Supplementary	Table	3).				
Gene	expression	patterns	associated	with	HCV	infection	in	vivo	and	in	vitro			We	next	sought	to	compare	the	transcriptional	responses	following	HCV	infection	in	vivo	and	in	vitro.	A	previous	genome-wide	analysis	of	differential	gene	expression	in	HCV-infected	Huh-7.5	cells	revealed	that	numerous	genes	involved	in	cell	death,	cell	cycle	and	cell	growth/proliferation	are	mis-regulated	following	viral	infection(Walters	et	al,	2009).	Although	our	unsupervised	gene	ontology	analyses	did	not	reveal	enrichments	
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for	cell	cycle-associated	categories	among	the	genes	differentially	expressed	in	CHC	samples	(Supplementary	Table	3),	we	found	significant	intersections	between	the	sets	of	genes	that	are	differentially	expressed	following	HCV	infection	in	vivo	and	in	vitro.	Specifically,	out	of	698	protein-coding	genes	differentially	regulated	in	HCV-infected	Huh-7.5	cells	(Methods),	we	found	that	25	(3.6%)	were	differentially	expressed	between	control	and	CHC	low	ISG	samples	and	48		(6.9%)	were	differentially	expressed	between	control	and	CHC	high	ISG	samples	(FDR<0.1,	Supplementary	Table	5).	The	extent	of	the	overlap	was	significantly	higher	than	expected	by	chance	given	the	total	number	of	differentially	expressed	genes,	in	both	cases	(Chi-square	test,	p-value	<1e-9).	The	common	differentially	regulated	genes	included	several	genes	associated	with	cell	death	and	cell	cycle,	such	as	UBD,	TNFRSF9,	BIRC3,	JUN,	FOS	etc.	(Supplementary	Table	5).	Differentially	expressed	genes	shared	between	HCV-infected	Huh7.5	cells	and	high	ISG	liver	biopsies	include	classical	ISGs,	such	as	MX1,	ISG15,	IFIT1	etc.	(Supplementary	Table	5),	as	expected	given	the	previously	reported	induction	of	interferon-stimulated	genes	in	these	cells(Walters	et	al,	2009).				
Gene	expression	changes	induced	by	pegIFNa	treatment			We	next	analyzed	the	gene	expression	changes	induced	by	pegIFNa/ribavirin	treatment	in	the	human	liver,	by	comparing	the	expression	profiles	of	control	and	post-treatment	biopsies	at	five	different	time	points	ranging	from	4	hours	to	144	hours	post-treatment	(Methods).	We	considered	genes	to	be	differentially	expressed	if	they	displayed	an	absolute	fold	change	of	at	least	2,	at	a	FDR	rate	of	5%	and	an	RPKM	value	above	1	in	at	least	one	of	the	compared	samples	(Methods).	With	these	stringent	criteria,	we	observed	numerous	expression	changes	at	all	time	points,	in	particular	for	protein-coding	genes,	but	also	affecting	other	categories	of	transcripts	(Fig.	5,	Supplementary	Table	6).	As	previously	reported(Dill	et	al,	2014),	most	differentially	expressed	protein-coding	genes	were	observed	at	16	hours	post-treatment,	followed	by	the	4	hours	time	point	(Fig.	5a).	We	observed	a	different	temporal	dynamics	for	differentially	expressed	non-coding	transcripts,	for	which	the	number	of	detected	up-regulated	genes	was	highest	at	the	4	hours	time	point	and	decreased	afterwards	(Fig.	5a).	Strikingly,	for	all	gene	categories	the	vast	majority	of	down-regulated	genes	were	observed	16	hours	after	treatment,	with	only	few	detected	cases	elsewhere	(Fig.	5a).		
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	At	all	time	points,	we	found	strong	enrichments	in	GO	categories	related	to	the	type	I	interferon	signaling	and	response	to	virus	pathways	among	the	genes	that	were	up-regulated	following	pegIFNa	treatment	(Supplementary	Table	7),	as	expected.	Consistently,	we	observed	that	interferon-stimulated	response	element	(ISRE)	motifs	and	IFN-regulatory	factors	(IRF)	motifs	were	strongly	enriched	in	the	promoters	of	up-regulated	protein-coding	genes,	at	all	time	points	(Supplementary	Fig.	5a-e).	For	down-regulated	genes,	we	found	significant	(FDR<0.1)	enrichments	in	functional	categories	related	to	small	molecule	biosynthetic	process	and	lipid	metabolism,	but	only	for	the	16h	time	point	(Supplementary	Table	7).			We	next	compared	the	sets	of	differentially	expressed	genes	observed	for	the	different	time	points.	We	observed	that	almost	60%	of	the	up-regulated	protein-coding	genes	passed	our	differential	expression	thresholds	at	a	single	time	point	(Fig.	5b).	For	up-regulated	lncRNAs	and	other	non-coding	genes,	the	time	point-specificity	was	even	stronger	(Fig.	5b).	However,	we	were	able	to	identify	a	core	set	of	60	genes	that	are	up-regulated	at	4	or	more	time	points,	including	31	genes	up-regulated	at	all	analyzed	time	points	(Supplementary	Table	8).	Interestingly,	3	lncRNAs	were	found	to	be	significantly	up-regulated	at	all	time-points	(Supplementary	Table	8,	Supplementary	Fig.	5f-h).	However,	two	of	these	lncRNAs	(including	NRIR,	a	lncRNA	previously	proposed	to	act	as	a	negative	regulator	of	interferon	response(Kambara	et	al,	2014))	are	found	downstream	of	interferon-stimulated	protein-coding	genes	(CMPK2	and	BST2),	and	our	RNA-seq	data	suggests	that	their	induction	may	be	at	least	in	part	due	to	leaky	transcription	from	the	upstream	gene	(Supplementary	Fig.	S5f-g).	No	such	neighborhood	effects	were	observed	for	the	third	lncRNA,	which	is	found	upstream	of	
RHOT1	(Supplementary	Fig.	S5h).	In	contrast	with	the	tendency	of	up-regulated	genes	to	be	shared	across	time	points,	down-regulated	genes	were	time	point-specific	in	more	than	80%	of	cases,	for	all	three	categories	of	genes	(Fig.	5b),	and	only	two	genes	(including	CD1C	and	a	newly	annotated	long	non-coding	RNA)	were	down-regulated	at	4	time	points	(Supplementary	Table	8).			
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Comparison	between	pegIFNa	treatment	and	endogenous	IFN	system	activation		The	induction	of	hundreds	of	ISGs	in	patients	with	CHC	has	little	impact	on	viral	replication,	whereas	treatment	of	patients	with	recombinant	pegIFNa	achieves	high	cure	rates	specifically	in	patients	without	an	activation	of	the	endogenous	IFN	system	in	the	liver(Heim,	2013;	Heim	&	Thimme,	2014).	To	investigate	the	molecular	differences	between	these	two	modes	of	IFN	system	activation,	we	compared	the	transcriptional	response	to	pegIFNa	treatment	with	the	one	elicited	by	the	endogenous	IFN	system	activation.	We	first	extracted	the	genes	that	are	significantly	up-	or	down-regulated	following	pegIFNa	treatment,	at	each	time	point,	and	analyzed	their	expression	differences	between	CHC	low	ISG	and	CHC	high	ISG	patients	(Fig.	6,	Supplementary	Table	9).	We	found	that	the	vast	majority	of	genes	that	are	up-regulated	upon	pegIFNa	treatment	are	also	induced	in	high	ISG	patients	(Fig.	6,	Supplementary	Table	9).	In	numerous	cases,	these	differences	were	also	statistically	significant	(FDR<10%)	in	the	comparison	between	low	ISG	and	high	ISG	patients	(Fig.	6).	However,	the	level	of	gene	induction	was	significantly	stronger	in	the	pegIFNa	treatment	analysis	(Fig.	6a),	as	were	the	absolute	levels	of	gene	expression	in	the	corresponding	samples	(Fig.	6c).	In	other	words,	the	ISG	expression	levels	reached	after	pegIFNa/ribavirin	treatment	are	higher	than	the	ones	observed	in	patients	with	high	endogenous	ISG	levels.	In	contrast,	genes	that	were	down-regulated	upon	pegIFNa	treatment	were	only	rarely	down-regulated	in	high	ISG	compared	to	low	ISG	patients	(Fig.	6b,d).	Similar	conclusions	were	reached	when	extracting	genes	that	are	significantly	differentially	expressed	between	low	ISG	and	high	ISG	patients	and	analyzing	their	expression	patterns	following	pegIFNa	treatment		(Supplementary	Fig.	6).	These	observations	suggest	that	the	endogenous	IFN	system	activation	and	its	external	stimulation	with	pegIFNa/ribavirin	treatment	have	qualitatively	similar	effects	on	the	gene	expression	patterns	on	the	human	liver	transcriptomes.	However,	numerous	quantitative	differences	in	the	two	transcriptional	responses	can	be	observed,	with	stronger	ISG	induction	levels	following	pegIFNa/ribavirin	treatment.		To	further	investigate	the	inability	of	the	endogenous	IFN	system	activation	to	cure	HCV	infections,	we	analyzed	the	expression	patterns	of	a	set	of	genes	proposed	to	act	as	antiviral	effectors,	selected	based	on	their	capacity	to	inhibit	HCV	replication	in	human	cell	lines(Metz	et	al,	2012;	Metz	et	al,	2013;	Schoggins	et	al,	2011)	(Methods).	We	
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analyzed	the	expression	of	these	genes	in	our	samples	(Fig.	7,	Supplementary	Table	10).	We	found	that	their	expression	levels	in	pegIFNa/ribavirin-treated	samples	and	in	high	ISG	samples	were	strongly	positively	correlated	(Fig.	7a).	However,	a	number	of	these	candidate	ISGs	were	indeed	significantly	more	stimulated	by	pegIFNa	than	by	endogenous	IFNs	in	high	ISG	patients	(Fig.	7a,	Supplementary	Table	10).	In	particular,	6	genes	(IRF1,	IRF2,	IRF7,	IRF9,	OASL,	IFITM3)	that	were	reported	as	antiviral	effectors	in	at	least	two	publications(Metz	et	al,	2013;	Schoggins	et	al,	2011)	did	not	differ	significantly	between	low	ISG	and	high	ISG	samples.		However,	with	the	exception	of	
IRF2,	all	of	them	appeared	to	be	induced	in	high	ISG	patients	compared	to	controls	or	low	ISG	patients,	albeit	at	weak	levels.	Thus	we	could	not	identify	ISGs	that	are	exclusively	induced	by	pegIFNa	and	that	could	be	bona	fide	anti-HCV	effector	genes.				
Down-regulated	microRNA	host	genes	following	pegIFNa	treatment		Our	analysis	of	the	dynamics	of	differentially	expressed	genes	following	pegIFNa	treatment	revealed	that	numerous	non-coding	transcripts	are	down-regulated,	in	particular	at	the	16h	time	point	(Fig.	5a).	We	noticed	that	these	down-regulated	genes	include	several	miRNA	“host”	genes	(defined	as	non-coding	transcripts	that	have	sense	exonic	overlap	with	annotated	miRNAs,	Methods).	In	total,	11	miRNA	host	genes	were	significantly	differentially	expressed	(FDR<0.05)	for	at	least	one	time	point,	and	all	instances	were	down-regulated	rather	than	up-regulated	(Fig.	8a).	Strikingly,	these	down-regulated	precursors	include	the	“host”	gene	of	miR-122,	which	enhances	HCV	replication	in	human	hepatocytes(Jopling	et	al,	2006)	(Fig.	8a,b).	The	estimated	decrease	in	expression	levels	is	likely	not	due	to	differential	processing	of	the	mature	miRNA	out	of	the	precursor	transcript,	as	consistent	differences	between	baseline	and	post-treatment	biopsies	were	observed	along	the	entire	gene	length	(Fig.	8b,	Supplementary	Fig.	7).	Among	the	other	miRNAs	whose	precursor	genes	are	down-regulated	upon	pegIFNa	treatment,	miR-146a	is	a	striking	example,	with	significant	down-regulation	(at	10%	FDR)	for	3	out	of	the	5	analyzed	time-points	(Fig.	8a).			Our	RNA-seq	dataset	does	not	allow	us	to	determine	whether	the	observed	down-regulation	of	miRNA	precursor	genes	affects	the	pool	of	mature	miRNAs	in	the	cells.	To	indirectly	test	this	hypothesis,	we	reasoned	that	a	decrease	in	mature	miRNA	expression	
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levels	should	positively	affect	the	expression	of	their	target	genes.	We	thus	analyzed	the	behavior	of	predicted	miRNA	target	genes	in	response	to	pegIFNa/ribavirin	treatment,	at	the	16h	time-point	(for	which	most	miRNA	host	down-regulation	events	were	observed,	Fig.	8a).	As	above,	we	analyzed	microRNAs	expressed	in	normal	and/or	HCV-infected	human	livers(Hou	et	al,	2011)	and	their	conserved	targets	predicted	computationally	with	TargetScan(Agarwal	et	al,	2015)	(Methods).	Strikingly,	out	of	57	miRNA	families	with	at	least	100	conserved	target	genes,	the	three	highest	median	expression	fold	changes	were	found	for	miRNAs	whose	precursor	genes	were	down-regulated	following	treatment:	miR-122,	miR-331	and	miR146a/b	(Fig.	8c).	High	median	fold	changes	were	also	observed	for	miR-214	and	miR-192	(Fig.	8c).			 	
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Discussion	Hepatitis	C	virus	(HCV)	is	one	of	the	most	widely	used	model	systems	to	investigate	host-virus	interactions.	The	adaptive	changes	to	HCV	infections	have	been	studied	extensively	in	cell	culture	systems.	For	example,	a	comprehensive	analysis	of	gene	expression	in	HCV	infected	Huh-7.5	cells	reported	over	800	genes	with	>	2-fold	changes	in	expression(Walters	et	al,	2009).	Adaptive	changes	were	described	in	lipid	biosynthetic	pathways,	endoplasmatic	reticulum	stress	response,	autophagy	and	cell	cycle	regulation.	However,	due	to	the	difficulties	inherent	to	human	liver	tissue	sampling,	few	of	these	findings	have	been	validated	in	vivo.	To	investigate	whether	the	observations	obtained	in	cell	culture	systems	can	be	confirmed	in	the	human	liver,	we	have	collected	and	analyzed	transcriptome	data	from	liver	biopsies	derived	from	control	and	chronic	hepatitis	C	patients,	in	the	absence	of	and	during	treatment	with	pegIFNa/ribavirin.				In	the	liver,	cell-intrinsic	adaptive	changes	to	HCV	infections	are	difficult	to	distinguish	from	changes	induced	by	the	immune	response.	In	experimentally	infected	chimpanzees,	transcriptome	analysis	revealed	a	strong	induction	of	hundreds	of	ISGs	in	all	animals(Bigger	et	al,	2004).	Due	to	a	genetic	polymorphism	in	the	IFNl4	gene,	ISG	induction	in	humans	is	variable(Prokunina-Olsson	et	al,	2013;	Terczynska-Dyla	et	al,	2014).	In	this	study,	in	order	to	reduce	the	strong	confounding	influence	of	the	endogenous	IFN	system,	we	analyzed	gene	expression	patterns	separately	for	patients	with	or	without	endogenous	IFN	activation.	We	found	that	gene	expression	changes	between	uninfected	liver	samples	and	low	ISG	samples	mainly	reflect	the	presence	of	immune	cell	infiltrates	in	the	latter	group.	However,	even	in	biopsies	from	patients	without	ISG	induction	(low	ISG	patients)	we	could	not	detect	expression	changes	of	genes	involved	in	cellular	responses	to	HCV	described	in	cell	culture.	For	example,	a	previous	large-scale	analysis	of	differential	gene	expression	in	HCV-infected	Huh-7.5	cells	revealed	that	numerous	genes	involved	in	cell	death,	cell	cycle	and	cell	growth/proliferation	are	mis-regulated	following	viral	infection(Walters	et	al,	2009),	while	our	differential	expression	analyses	did	not	reveal	enrichments	for	these	functional	categories	of	genes.	We	therefore	used	a	targeted	approach	and	specifically	analyzed	genes	previously	reported	to	be	changed	in	HCV-infected	Huh-7.5	cells(Walters	et	al,	2009).	Specifically,	we	could	identify	a	core	set	of	25	genes	that	are	
	 44	
differentially	expressed	following	HCV	infection	in	both	Huh	7.5	cells	and	in	liver	samples	from	patients	without	IFN	system	activation.	This	common	gene	set	included	several	cell	cycle	associated	genes,	such	as	UBD,	ITIH1,	BIRC3	etc.	(Supplementary	Table	5)(Walters	et	al,	2009).	Thus,	we	were	able	to	identify	a	significant	number	of	genes	that	respond	to	HCV	infection	both	in	vivo	and	in	vitro.		How	might	we	explain	the	differences	in	HCV-induced	expression	patterns	in	vivo	and	in	
vitro?	It	has	been	estimated	that	the	number	of	HCV	virions	per	infected	cell	is	between	1	and	8	in	the	human	liver,	but	can	be	as	high	as	500	to	1000	in	the	Huh-7.5	cell	culture	model(Stiffler	et	al,	2009).	It	is	thus	conceivable	that	some	of	changes	described	in	cell	culture	are	due	to	the	high	viral	concentration,	and	do	not	occur	in	vivo.	However,	it	is	also	possible	that	our	analysis	was	underpowered	to	detect	HCV-induced	cell-intrinsic	changes	in	gene	expression.	Changes	in	infected	hepatocytes	could	be	masked	by	unchanged	gene	expression	in	non-infected	hepatocytes	and	non-parenchymal	liver	cells	(endothelial	cells,	biliary	epithelial	cells,	stellate	cells,	fibroblasts	and	Kupffer	cells).	Non-parenchymal	cells	provide	about	one	third	of	the	liver	mass,	and	the	number	of	infected	hepatocytes	can	vary	from	1%	to	55%(Wieland	et	al,	2014).	To	minimize	the	information	dilution	from	uninfected	cells,	we	preferentially	included	in	our	study	samples	from	patients	with	high	viral	load,	because	the	proportion	of	infected	cells	significantly	correlates	with	serum	viral	load(Wieland	et	al,	2014).	Nevertheless,	we	cannot	exclude	that	because	of	these	limitations	we	could	not	detect	some	genuine	HCV-induced	cell-intrinsic	changes	of	gene	expression.	
	We	also	addressed	a	long-standing	conundrum	in	the	field	regarding	the	inability	of	the	endogenous	IFN	system	activation	to	eradicate	HCV	infections.	Ever	since	the	discovery	that	a	substantial	proportion	of	patients	with	CHC	have	a	strong	induction	of	hundreds	of	ISGs	in	the	liver(Asselah	et	al,	2008;	Chen	et	al,	2005;	Sarasin-Filipowicz	et	al,	2008)	it	remained	unclear	why	the	endogenous	IFN	system	is	ineffective	against	HCV,	whereas	therapies	with	recombinant	(pegylated)	IFNa	were	curative	in	many	patients.	Two	alternative	explanations	were	discussed:	Either	some	critical	ISGs	are	exclusively	induced	by	pegIFNa,	or	pegIFNa	induces	the	same	ISGs	but	at	a	higher	level	than	the	endogenous	IFNs.	At	first	sight,	our	results	indicate	that	the	number	of	significantly	changed	ISGs	is	much	higher	after	pegIFNa	compared	to	those	induced	by	endogenous	IFNs	(in	high	ISG	samples),	suggesting	that	pegIFNa	indeed	induces	additional	ISGs	that	
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are	not	stimulated	by	endogenous	IFNS.	However,	most	of	these	“additional”	genes	were	up-regulated	in	high	ISG	samples	as	well,	albeit	to	a	lesser	degree	and	therefore	not	passing	the	significance	threshold.	Such	quantitative	differences	were	also	observed	for	a	number	of	candidate	anti-HCV	effector	ISGs	identified	in	large	screens(Metz	et	al,	2013;	Schoggins	et	al,	2011).	Most	of	them	were	significantly	stronger	induced	by	pegIFNa	compared	to	endogenous	IFNs,	but	their	expression	levels	were	highly	positively	correlated	between	samples	treated	with	pegIFNa/ribavirin	and	samples	with	high	endogenous	ISG	levels	(Fig.	7,	Supplementary	Table	10).	We	present	6	candidate	antiviral	effectors	(IRF1,	IRF2,	IRF7,	IRF9,	OASL,	IFITM3,	reported	in	both	publications	cited	above(Metz	et	al,	2013;	Schoggins	et	al,	2011))	that	do	not	differ	significantly	between	low	ISG	and	high	ISG	patients.	However,	with	the	exception	of	IRF2,	these	genes	also	appear	to	be	slightly	induced	in	high	ISG	samples	compared	to	low	ISG	or	non-infected	samples,	although	at	lower	levels	(Fig.	7).	Of	note,	IRF2	stands	out	because	it	is	induced	by	pegIFNa	at	the	4h	time	point,	but	appears	to	down-regulated	by	endogenous	IFNs	(Fig.	7).	However,	IRF2	is	unlikely	to	be	an	antiviral	effector	sensu	stricto.	IRF2	is	a	transcriptional	regulator	involved	in	IFN	induction	and	in	IFN	signaling(Ikushima	et	al,	2013).	Our	in	vivo	analysis	therefore	could	not	reliably	identify	a	set	of	ISG	effectors	uniquely	up-regulated	by	pegIFNa	that	could	be	responsible	for	the	superior	antiviral	efficacy	of	the	treatment.	Thus,	our	current	analysis	for	the	first	time	provides	strong	evidence	that	quantitative	rather	than	qualitative	differences	in	gene	induction	are	responsible	for	the	failure	of	the	endogenous	IFNs	and	the	success	of	pegIFNa	in	viral	eradication.		We	also	addressed	the	contribution	of	non-coding	RNAs	to	gene	regulation	in	response	to	HCV	infections	and	to	pegIFNa	treatments.	Most	prominent	of	them	is	miR-122,	because	it	is	an	essential	host	factor	for	HCV	replication(Jopling	et	al,	2005).	The	fascinating	role	of	the	highly	abundant	miR-122	in	HCV	replication	and	virus-host	interaction	has	recently	been	enriched	by	the	observation	that	binding	of	miR-122	by	HCV	can	regulate	host	gene	expression	by	reducing	(sponging)	the	amount	of	miR-122	available	for	gene	repression(Luna	et	al,	2015).	Detailed	functional	experiments	in	Huh7	cells	brought	evidence	that	HCV	infection	leads	to	significant	de-repression	of	miR-122	target	genes	due	to	this	sponging	effect(Luna	et	al,	2015).	At	first	sight,	our	in	vivo	transcriptomic	analysis	appeared	to	confirm	this	observation,	as	miR-122	target	genes	had	higher	expression	levels	in	HCV-infected	compared	to	control	biopsies,	more	so	than	
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genes	targeted	by	all	other	miRNAs	and	than	genes	that	are	not	targets	of	miRNAs	(Figure	2,3).	However,	a	closer	look	revealed	the	same	pattern	for	other	miRNAs	highly	expressed	in	the	liver	(e.g.,	miR-192,	let-7).	Because	HCV	does	not	bind	these	other	miRNAs,	this	observation	cannot	be	simply	explained	by	a	sponging	effect.			An	unexpected	observation	from	our	analysis	of	the	transcriptional	response	to	pegIFNa/ribavirin	treatment	was	that	11	long	non-coding	transcripts	that	act	as	precursors	for	miRNAs	(miRNA	“host”	genes)	are	significantly	down-regulated	following	treatment.	Strikingly,	the	precursor	transcript	of	miR-122	is	part	of	these	down-regulated	transcripts.	Moreover,	the	genes	targeted	by	these	down-regulated	miRNAs	had	the	highest	median	expression	fold	changes	following	treatment.	This	indicates	that	the	expression	changes	observed	for	the	precursor	transcripts	are	reflected	in	the	mature	miRNA	levels.	This	finding	is	in	agreement	with	previous	evidence	that	IFNbeta	treatment	decreases	mature	miR122	levels(Pedersen	et	al,	2007),	and	that	miR-122	levels	are	lower	in	individuals	with	endogenous	IFN	system	activation(Sarasin-Filipowicz	et	al,	2009).	Interestingly,	besides	miR-122,	several	other	miRNAs	whose	host	genes	are	down-regulated	have	been	associated	with	HCV	infections	and/or	interferon	treatment.	For	example,	miR-146a	was	previously	reported	to	inhibit	type	I	interferon	production(Ho	et	al,	2014;	Hou	et	al,	2009).	Its	down-regulation	following	pegIFNa/treatment	might	thus	allow	for	a	sustained	activation	of	ISGs	and	thus	more	effective	antiviral	response.	Another	example	is	miR-192,	which	was	previously	proposed	as	a	predictor	for	the	response	to	IFN	treatment(Motawi	et	al,	2015).	Finally,	it	is	tempting	to	speculate	that	the	down-regulation	of	miR-122	levels	might	contribute	to	the	efficiency	of	the	pegIFNa/ribavirin	treatment	in	eliminating	HCV	infections.			In	conclusion,	this	comprehensive	gene	expression	analysis	with	liver	biopsy	samples	(obtained	before	and	during	treatment	with	pegIFNa)	from	patients	with	HCV	infection	revealed	that	HCV	has	no	strong	effect	on	the	homeostasis	of	infected	cells,	that	the	endogenous	IFN	response	is	qualitatively	similar	to	pegIFNa	treatment	but	too	weak	to	clear	the	infection	and	that	IFN	down-regulates	miRNA	precursor	transcripts,	thereby	fine-tuning	ISG	expression.			 	
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Methods	
Patient	selection	The	study	included	25	patients	with	chronic	hepatitis	C	(CHC)	and	6	control	patients	(not	infected	with	HCV)	who	underwent	a	diagnostic	liver	biopsy	in	the	outpatient	clinic	of	the	Division	of	Gastroenterology	and	Hepatology,	University	Hospital	Basel.	The	patients	agreed	to	participate	in	the	study	and	written	informed	consent	was	obtained	(approved	by	the	ethics	commission	of	the	cantons	Basel-Stadt	and	Basel-Land;	approval	number	EKBBM189/99).	All	patients	with	CHC	were	screened	for	potential	response	to	treatment	using	a	previously	published	classification	method	based	on	the	expression	values	of	IFI27,	RSAD2,	ISG15	and	HTATIP2	(Dill	et	al,	2011).	Patients	with	high	probability	of	achieving	sustained	virologic	response	(SVR)	were	identified	and	in	case	of	planned	IFN-based	treatment	they	were	asked	to	undergo	a	second	liver	biopsy.	Nineteen	patients	agreed	to	undergo	a	second	biopsy,	as	follows:	after	4h	(5	patients),	16h	(3	patients),	48h	(3	patients),	96h	(3	patients)	or	144h	(5	patients)	of	the	first	therapeutic	injection	of	pegylated	interferons	(pegIFNs).	PegIFNs/Ribavirin	doses	were	set	according	to	HCV	genotype	and	body	weight	based	on	standard	recommendations.	PegIFNs	were	administered	subcutaneously	once	weekly	at	the	initial	dose	of	1.5	μg/kg	body	weight	of	pegIFNα-2b	(Essex	Chemie)	or	180	μg	of	pegIFNα-2a	(Roche).	Serum	HCV	RNA	was	quantified	using	the	COBAS	AmpliPrep/COBAS	TaqMan	HCV	Test	and	the	COBAS	Amplicor	Monitor	from	Roche.	Diagnosis	of	control	patients	was	based	on	clinical,	laboratory,	and	histopathological	assessment.	For	18	patients,	microarray-based	expression	analyses	of	the	biopsy	material	were	previously	published(Dill	et	al,	2014).	One	additional	patient	was	included	for	the	16h	time	point.	Patient	characteristics	are	summarized	in	Supplementary	Table	1.	
RNA-seq	data	generation	Total	RNA	was	extracted	from	fresh-frozen	bulk	liver	biopsy	tissue	using	Trizol	reagent	(Invitrogen)	and	subsequently	subjected	to	DNase	treatment	using	DNA-free™	DNA	Removal	Kit	(Ambion)	according	to	manufacturer’s	instructions.	RNA	concentration	was	determined	using	NanoDrop	2000	spectrophotometer	(Thermo	Scientific)	and	RNA	quality/integrity	was	assessed	with	an	Agilent	2100	BioAnalyzer	using	RNA	6000	Nano	Kit	(Agilent	Technologies).	All	46	RNA	samples	included	in	this	study	had	RNA	integrity	number	(RIN)	values	of	>7	(7.1-9.4;	median	8.9),	with	42	out	of	46	samples	having	RIN	
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values	≥8.	We	generated	RNA	sequencing	(RNA-seq)	data	using	the	Illumina	TruSeq	Stranded	mRNA	protocol,	with	polyA	selection.	The	libraries	were	sequenced	on	an	Illumina	HiSeq	2500	machine,	as	single-end	reads.			
RNA-seq	data	processing	The	RNA-seq	reads	were	trimmed	to	remove	3’	end	adapter	sequences,	keeping	a	maximum	read	length	of	81	bp.	The	reads	were	aligned	on	the	hg38	primary	assembly	(excluding	patches	and	haplotypic	sequences)	of	the	human	genome,	downloaded	from	the	Ensembl(Cunningham	et	al,	2015)	database	release	76.	The	alignments	were	done	using	TopHat(Kim	et	al,	2013)	release	2.0.10	and	Bowtie(Langmead	&	Salzberg,	2012)	release	2.1.0.	We	allowed	intron	sizes	between	40	bp	and	1	million	bp	for	spliced	read	alignments,	with	a	minimum	anchor	size	of	8	bp	and	a	maximum	of	1	mismatch	for	each	aligned	read	segment.		
Gene	model	reconstruction	with	RNA-seq	We	used	Cufflinks(Trapnell	et	al,	2010)	release	2.2.1	to	reconstruct	de	novo	gene	models	from	TopHat	unique	read	alignments.	Reads	with	multiple	reported	alignments	were	excluded	from	the	dataset	prior	to	de	novo	reconstruction.	We	kept	isoforms	with	a	minimum	frequency	above	0.05.	Intra-intronic	transcripts	(corresponding	to	retained	introns	or	unspliced	pre-mRNAs)	were	kept	if	their	frequency	was	above	0.25.	We	allowed	intron	sizes	between	40	bp	and	500,000	bp.	Neighboring	transcribed	regions	were	collapsed	if	they	were	closer	than	40	bp.	We	performed	the	gene	model	reconstruction	separately	for	each	RNA-seq	sample	and	then	merged	them	into	a	single	set	of	gene	models	using	the	cuffmerge	tool	in	Cufflinks.	We	note	that	de	novo	reconstructed	gene	models	may	be	fragmented,	meaning	that	a	single	locus	can	be	split	into	several	predicted	gene	models,	in	particular	for	low	expression	levels.	
Long	non-coding	RNA	dataset	We	used	genomic	annotations	from	the	Ensembl(Cunningham	et	al,	2015)	database	release	82	as	a	basis	for	our	analyses,	to	which	we	added	de	novo	gene	models	reconstructed	with	Cufflinks.	We	determined	the	protein-coding	potential	of	de	novo	gene	models	based	on	the	codon	substitution	frequency	(CSF)	score	approach(Lin	et	al,	2007;	Lin	et	al,	2011)	and	on	sequence	similarity	with	known	protein	databases	(SwissProt(UniProt,	2015))	and	protein	domains	(Pfam-A(Finn	et	al,	2014)),	as	previously	described(Necsulea	et	al,	2014).	For	the	CSF	approach,	to	determine	the	
	 49	
codon	substitution	frequencies	expected	for	coding	and	non-coding	regions,	we	aligned	Ensembl-annotated	protein-coding	sequences	and	intronic	regions,	for	9,000	1-1	orthologous	gene	families	for	42	vertebrate	species	extracted	from	the	Ensembl	Compara	database(Vilella	et	al,	2009).	We	then	counted	all	observed	codon	substitutions	and	constructed	coding	and	non-coding	substitution	matrices.	We	downloaded	whole	genome	alignments	for	human	and	99	other	vertebrate	genomes	from	the	UCSC	Genome	Browser(Rosenbloom	et	al,	2015)	and	we	computed	the	CSF	score	in	75	bp	sliding	windows	along	the	entire	human	genome,	as	described	previously(Necsulea	et	al,	2014).	We	then	extracted	all	genomic	regions	with	positive	CSF	scores.	As	positive	CSF	scores	can	appear	spuriously	on	the	opposite	strand	of	protein-coding	regions(Cabili	et	al,	2011),	for	regions	with	positive	CSF	scores	on	both	strands	we	considered	only	the	strand	with	the	highest	score.	Gene	models	were	classified	as	potentially	protein-coding	if	had	positive	CSF	scores	over	at	least	90	bp	or	25%	of	their	exonic	length.	In	addition,	we	searched	for	sequence	similarity	between	exonic	sequences	and	known	proteins	from	and	protein	domains	from	the	SwissProt(UniProt,	2015)		and	Pfam-A(Finn	et	al,	2014)	databases,	using	blastx(Altschul	et	al,	1990).	We	kept	SwissProt	proteins	with	high	confidence	annotations	(protein	existence	score	1,	2	or	3).	We	retained	blastx	hits	with	e-values	below	0.001.	Gene	models	were	classified	as	potentially	protein-coding	if	they	had	significant	blastx	hits	with	SwissProt	or	Pfam-A	protein	sequences	over	at	least	90	bp	or	5%	of	their	exonic	length.	De	novo	reconstructed	gene	models	classified	as	non-coding	with	both	approaches	were	kept	for	further	long	non-coding	RNA	analyses.		To	avoid	annotating	alternative	untranslated	regions	or	introns	of	protein-coding	genes	as	independent	long	non-coding	RNAs,	we	further	filtered	the	set	of	de	novo-predicted	lncRNAs	based	on	their	distance	to	Ensembl-annotated	protein-coding	genes.	We	retained	lncRNA	candidates	that	had	no	sense	overlap	with	Ensembl-annotated	protein-coding	genes	and	that	were	at	least	10	kilobases	(kb)	away	from	protein-coding	gene	coordinates.	Sense	intronic	overlaps	with	other	non-coding	transcripts	were	accepted.	We	discarded	loci	with	an	exonic	length	below	200	bp	(for	multi-exonic	loci)	or	500	bp	(for	mono-exonic	loci).	We	further	excluded	loci	overlapping	with	RNA	repeats	or	with	UCSC-annotated	retro-transposed	gene	copies	over	more	than	10%	of	their	length.				In	addition	to	de	novo	predicted	lncRNA	candidates,	we	analyzed	Ensembl-annotated	transcripts	corresponding	to	gene	biotypes	“lincRNA”,	“processed_transcript”	or	
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“antisense”.	For	both	Ensembl-annotated	and	de	novo	predicted	lncRNAs,	we	further	required	support	from	at	least	50	uniquely	mapped	RNA-seq	reads,	across	all	RNA-seq	samples	pooled	together.	In	total,	we	analyzed	8,912	candidate	lncRNAs,	including	4,246	candidates	detected	de	novo	and	4,666	Ensembl-annotated	lncRNAs.	The	de	novo	annotated	lncRNA	coordinates	are	provided	with	our	GEO	submission	(accession	number	GSE84346).	
Gene	expression	estimation	We	computed	expression	levels	for	protein-coding	genes	and	candidate	long	non-coding	RNAs	derived	from	Ensembl	annotations	or	predicted	de	novo	with	RNA-seq.	For	genes	that	had	multiple	isoforms,	we	combined	exon	coordinates	from	all	isoforms	into	a	single	“flattened”	gene	model	and	computed	a	single	expression	level	for	each	gene.	For	protein-coding	genes,	only	protein-coding	isoforms	were	kept,	discarding	retained	introns	and	other	potentially	non-functional	isoforms.	We	used	two	approaches	to	estimate	gene	expression	levels.	First,	we	estimated	gene-based	RPKM	(reads	per	kilobase	of	exon	per	million	mapped	reads)	values	by	counting	uniquely	mapped	RNA-seq	reads	that	overlapped	with	exon	coordinates	over	at	least	5	bp.	RNA-seq	reads	that	were	mapped	to	sense-overlapping	exonic	regions	were	added	to	the	read	count	of	all	corresponding	genes.	The	total	number	of	mapped	reads	for	each	sample	(corresponding	to	the	M	denominator	in	the	RPKM	computation)	was	computed	after	discarding	ambiguously	mapped	reads	and	reads	that	aligned	to	the	mitochondrial	genome.	We	normalized	expression	levels	among	samples	using	a	previously	described	median-scaling	procedure,	based	on	the	least-varying	genes	in	terms	of	expression	ranks(Brawand	et	al,	2011).	Second,	we	used	Cufflinks	to	estimate	gene	expression	levels	using	all	TopHat-aligned	reads,	assigning	reads	with	multiple	alignments	to	each	gene	depending	on	gene	expression	levels	estimated	with	unique	reads	(default	multiple	read	correction	procedure	in	Cufflinks).	All	gene	expression	estimates	are	provided	with	our	GEO	submission	(accession	number	GSE84346).	
Differential	gene	expression	We	assessed	differential	gene	expression	using	methods	in	the	DESeq2(Love	et	al,	2014)	package	(release	1.10.0)	in	R/Bioconductor	(release	3.2.2),	starting	from	the	numbers	of	unambiguous	read	counts	assigned	to	each	gene.	To	test	for	differential	gene	expression	following	pegIFNa/ribavirin	treatment,	we	used	a	likelihood	ratio	test	to	compare	two	
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generalized	linear	models:	a	full	model	with	two	explanatory	variables	(the	control/treated	condition	and	the	individual)	and	the	reduced	model	with	the	individual	as	a	single	explanatory	variable.	To	test	for	differential	gene	expression	between	groups	of	patients	(normal	liver,	CHC	high	ISG	or	CHC	low	ISG),	we	compared	a	model	with	one	explanatory	variable	(the	patient	group)	and	the	null	model,	according	to	which	the	patient	group	has	no	effect.	For	the	comparison	between	normal	liver,	CHC	high	ISG	and	CHC	low	ISG	patients,	we	further	selected	the	samples	based	on	their	METAVIR	score	for	inflammation	and	fibrosis		(A1/F1,	A1/F2	and	A2/F2	samples	were	kept	for	further	analyses).	We	also	excluded	one	sample	(identifier	A707),	which	had	high	expression	levels	for	inflammatory	markers	despite	its	A2/F2	METAVIR	classification.	The	sets	of	patients	analyzed	for	each	test	are	provided	in	Supplementary	Table	1.		P-values	were	corrected	for	multiple	testing	using	the	Benjamini-Hochberg	method,	as	implemented	in	DESeq2.	Note	that	for	some	genes,	the	resulting	false	discovery	rate	(FDR)	is	set	to	“NA”,	if	the	expression	levels	are	too	low	or	too	variable	to	ensure	reliable	differential	expression	estimates(Love	et	al,	2014).	For	further	analyses,	we	selected	genes	for	which	the	RPKM	level	was	above	1	in	at	least	one	of	the	compared	samples.		
Resampling	to	control	for	outlier	effects	in	differential	expression	analyses	The	level	of	endogenous	IFN	system	activation	can	vary	among	patients	classified	as	high	ISG	(Figure	1).	In	addition,	our	dataset	included	different	number	of	patients	in	the	control	(6),	low	ISG	(7)	and	high	ISG	(7)	categories,	which	may	affect	the	statistical	power	of	the	analysis.	To	avoid	outlier	effects	in	our	differential	expression	analyses	for	these	comparisons	(contrasting	non-CHC,	low	ISG	and	high	ISG	patients),	we	resampled	6	out	7	patients	for	the	low	ISG	and	high	ISG	categories	and	we	performed	differential	expression	analyses	with	the	reduced	number	of	samples.	All	possible	patient	combinations	were	tested	separately.	We	then	selected	gene	expression	differences	based	on	their	average	false	discovery	rates	(FDR)	and	average	log2-fold	expression	change	level	across	all	resampling	replicates.	The	analyses	presented	in	the	manuscript	correspond	to	this	resampling	correction.	Similar	conclusions	were	reached	when	differential	expression	analyses	were	performed	with	all	samples	(results	provided	in	Supplementary	Table	2).	For	these	comparisons,	we	considered	that	genes	are	differentially	expressed	if	the	FDR	was	below	0.1	and	the	absolute	fold	change	above	1.5.	We	voluntarily	chose	slightly	less	restrictive	FDR	and	fold	change	thresholds	for	these	
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analyses	than	for	the	pegIFNa	treatment	analysis,	to	avoid	a	loss	of	sensitivity	associated	with	this	resampling	procedure.		
Gene	ontology	enrichment	We	performed	gene	ontology	enrichment	analyses	using	the	GOrilla	webserver(Eden	et	al,	2009).	We	contrasted	a	focus	set	of	genes	(e.g.,	genes	that	were	up-regulated	in	a	set	of	patients	or	at	one	time	point	during	treatment)	with	a	background	set	of	genes	expressed	at	in	the	same	samples.	We	set	the	false	discovery	rate	for	the	GO	enrichment	analysis	at	0.1.	Only	protein-coding	genes	were	used	for	this	analysis.	We	also	downloaded	GO	associations	for	each	Ensembl-annotated	gene	from	the	Ensembl	82	database,	using	BioMart.	For	the	principal	component	analysis	(PCA)	presented	in	Supplementary	Fig.	1,	we	selected	genes	associated	with	the	categories:	"type	I	interferon	production",	"response	to	type	I	interferon",	"response	to	interferon-gamma".		
Transcription	factor	binding	enrichment	analysis	We	used	HOMER(Heinz	et	al,	2010)	to	assess	the	enrichment	of	transcription	factor	binding	motifs	in	the	promoter	regions	of	differentially	expressed	protein-coding	genes,	compared	to	the	genomic	background.	We	searched	for	motifs	in	a	500	bp	region,	starting	400	bp	upstream	of	the	transcription	start	site	and	ending	100	bp	downstream.	For	each	analysis,	we	display	the	enriched	motif,	its	frequency	among	the	tested	genes	and	the	enrichment	with	respect	to	the	background.		
microRNA	expression		To	evaluate	the	involvement	of	miRNA	regulation	in	the	gene	expression	differences	observed	between	patient	categories	or	following	treatment,	we	first	obtained	a	dataset	of	miRNAs	expressed	in	the	relevant	samples.	We	downloaded	miRNA	expression	values	evaluated	with	RNA	sequencing	and	measured	as	TPM	(tags	per	million	mapped	reads)	from	a	previous	publication(Hou	et	al,	2011).	This	dataset	included	expression	levels	for	normal	liver,	hepatitis	B	virus	(HBV)-infected	and	HCV-infected	liver	and	hepatocellular	carcinoma	from	HBV	and	HCV-infected	livers.	For	comparability	with	our	samples,	we	retained	only	expression	levels	from	normal	liver	and	HCV-infected,	non-carcinoma	samples.	We	summed	the	TPM	values	across	all	relevant	samples	and	ranked	miRNAs	based	on	their	combined	expression	values.	For	miRNA	target	analyses,	we	retained	miRNAs	with	a	combined	TPM	value	of	at	least	100.		
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microRNA	target	prediction		We	used	two	sources	for	miRNA	target	predictions.	First,	we	extracted	computational	target	predictions	from	the	TargetScan	v7.1	human	dataset(Agarwal	et	al,	2015).	To	enrich	in	reliable	target	predictions,	we	kept	only	gene-miRNA	associations	that	had	a	cumulative	context++	score(Agarwal	et	al,	2015)	below	0.	We	analyzed	separately	miRNA-target	gene	relationships	for	which	at	least	one	conserved	binding	site	was	predicted.	Second,	we	used	target	predictions	determined	experimentally	with	HITS-CLIP	in	Huh7	cells(Luna	et	al,	2015).	This	dataset	included	binding	sites	for	50	miRNAs	expressed	in	Huh7	cells.	We	filtered	this	dataset	to	keep	only	binding	sites	found	in	the	3’	UTR	region	and	we	excluded	6mer	binding	sites.	For	the	TargetScan	dataset,	we	analyzed	only	miRNAs	that	were	expressed	in	normal	and	HCV-infected	liver,	as	defined	above.	All	data	are	provided	in	Supplementary	Table	4.	For	the	analysis	of	miRNA	targets	and	their	expression	patterns,	we	always	exclusively	analyzed	genes	that	are	expressed	at	an	RPKM	level	of	at	least	1	in	at	least	one	of	the	relevant	samples.	For	the	analysis	presented	in	Fig.	8,	we	computed	confidence	intervals	for	the	median	expression	fold	change	(following	pegIFNa/ribavirin	treatment	at	the	16h	time	point)	with	a	bootstrap	approach,	by	resampling	the	same	number	of	genes	100	times	with	replacement.	We	then	extracted	the	2.5%	and	97.5%	quantiles	of	the	resulting	distribution,	which	are	displayed	as	confidence	intervals	in	Fig.	8.	
Definition	of	microRNA	host	genes	Our	RNA-seq	dataset	allows	us	to	estimate	expression	levels	for	all	long,	poly-adenylated	transcripts,	thus	in	principle	including	miRNA	primary	transcripts.	We	extracted	coordinates	of	miRNA	transcripts	from	Ensembl	82(Cunningham	et	al,	2015)	and	we	analyzed	their	overlap	with	exons	of	Ensembl-annotated	or	de	novo-detected	non-coding	RNA	genes.	We	found	a	total	of	70	lncRNAs	that	had	exonic	overlap	with	miRNAs,	that	we	classified	as	potential	“miRNA	host	genes”	and	included	in	further	analyses	(Supplementary	Table	11).	We	did	not	include	in	this	analysis	genes	with	intronic	overlap	with	miRNAs.		
Antiviral	effector	datasets	We	specifically	analyzed	the	expression	patterns	of	a	subset	of	ISGs	that	were	previously	proposed	to	act	as	antiviral	effectors	through	a	large-scale	over-expression	screening	approach	in	Huh-7.5	cells	(Schoggins	et	al,	2011).	We	extracted	the	list	of	genes	whose	
	 54	
over-expression	had	a	negative	on	HCV	replication	in	this	experimental	setup,	at	both	48h	and	72h	time	points,	and	matched	them	with	current	Ensembl	annotations	by	gene	names.	Genes	that	appeared	as	having	both	positive	and	negative	effects	on	HCV	replication	(depending	on	the	time-points)	were	excluded.	We	added	to	this	list	of	genes	a	dataset	of	ISG	antiviral	effectors	previously	described(Metz	et	al,	2013),	including	genes	whose	antiviral	properties	were	predicted	with	a	knockdown	approach(Metz	et	al,	2012).	The	gene	lists	are	provided	in	Supplementary	Table	10.	
Differentially	expressed	genes	in	HCV-infected	Huh7	cells	We	also	analyzed	a	set	of	genes	previously	shown	to	be	differentially	expressed	following	HCV	infection	in	Huh-7.5	cells(Walters	et	al,	2009).	We	matched	the	list	of	genes	with	Ensembl	82	annotations	using	the	RefSeq	accession	number	provided	in	this	dataset(Walters	et	al,	2009).	The	gene	lists	and	their	differential	expression	patterns	are	provided	in	Supplementary	Table	5.		
Tissue	expression	patterns	from	GTEx		We	analyzed	the	spatial	expression	patterns	of	the	various	gene	lists	identified	in	our	study,	using	the	gene	expression	dataset	of	the	GTEx	consortium,	release	v6(Mele	et	al,	2015).	We	downloaded	the	pre-computed	median	RPKM	values	per	tissue	from	the	GTEx	server.	We	used	this	dataset	to	estimate	the	tissue	in	which	each	gene	reaches	its	maximum	expression,	for	genes	for	which	the	maximum	RPKM	value	in	GTEx	tissues	was	at	least	1.		
Statistics	and	graphics	All	data	analyses	and	graphical	representations	were	done	in	R.	The	principal	component	analyses	were	performed	with	functions	implemented	in	the	ade4	library.		
Data	availability	All	raw	and	processed	RNA-seq	data,	including	de	novo	gene	annotations	obtained	with	Cufflinks	and	all	expression	estimations,	are	available	in	the	GEO	database	(accession	number	GSE84346).	The	data	is	available	during	the	review	process	at	the	
following	link:		http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kjkfsqielxqjlen&acc=GSE84346				 	
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Figures			
Figure	1.		
	
	
	
	
a.	Expression	levels	of	20	interferon-stimulated	genes	(ISGs)	in	28	liver	biopsies	from	HCV	and	non-HCV	patients,	in	the	absence	of	treatment.	These	ISGs	were	previously	detected	as	consistently	stimulated	by	pegIFNa	across	5	time	points	between	4h	and	144h,	in	chronic	hepatitis	C	(CHC)	patients(Dill	et	al,	2014).	The	heatmap	represents	the	Z-score	(centered	and	scaled	values)	of	log2-transformed	RPKM	(reads	per	kilobase	of	exon	per	million	mapped	reads)	expression	levels,	normalized	based	on	housekeeping	genes	(Methods).	The	samples	(columns)	and	genes	(rows)	were	hierarchically	clustered	based	on	pairwise	Euclidean	distances.	The	HCV	genotype,	the	METAVIR	scores	for	inflammation	(A0	to	A3)	and	fibrosis	(F0	to	F4)	are	displayed	for	each	patient.	Blank	rectangles	correspond	to	non-infected	samples.		
b.	Barplot	of	the	HCV	viral	load	for	each	patient,	ordered	as	in	A.	Blank	spaces	correspond	to	non-infected	samples.			 	
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Figure	2.		
	
	
	
	
	
a.	Volcano	plot	for	the	differential	expression	analysis	between	non-CHC	patients	and	CHC	patients	with	low	levels	of	endogenous	ISG	activation	(CHC	low	ISG).	The	X-axis	represents	the	log2	fold	expression	change	in	CHC	low	ISG	patients	compared	to	non-CHC	patients.	The	Y-axis	represents	the	false	discovery	rate	(with	a	-log10	transformation)	of	the	differential	expression	test.	Protein-coding	genes,	candidate	long	non-coding	RNAs	(lncRNAs)	and	other	gene	categories	(including	pseudogenes	and	transcripts	with	unclear	coding	potential,	Methods)	are	represented	separately.	Genes	with	false	discovery	rate	(FDR)	<	10%	and	with	fold	expression	change	>=	1.5	are	shown.		
b.	Heatmap	of	the	expression	patterns	of	the	top	differentially	expressed	protein-coding	genes.	We	set	a	fold	change	threshold	of	3	for	up-regulated	genes	and	of	0.5	for	down-
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regulated	genes.	The	heatmap	represents	the	Z-score	of	the	log2-transformed	RPKM	(reads	per	kilobase	of	exon	per	million	mapped	reads)	gene	expression	levels,	normalized	based	on	housekeeping	genes	(Methods).	
c.	Barplots	representing	the	expression	patterns	of	three	categories	of	genes	(all	expressed	genes,	genes	up-regulated	in	CHC	low	ISG	samples,	and	genes	down-regulated	in	CHC	low	ISG	samples	compared	to	control	non-CHC	samples),	in	the	GTEx	tissue	transcriptome	collection.	For	each	expressed	gene,	we	scored	the	tissue	or	cell	type	in	which	its	maximum	expression	level	was	reached	(Methods).	The	height	of	the	rectangles	represents	the	percentage	of	genes	that	reaches	maximum	expression	in	each	of	the	tissues.		
d.	Boxplots	of	the	intensity	of	the	expression	change	(log2	fold)	between	non-CHC	patients	and	CHC	low	ISG	patients,	for	different	categories	of	protein-coding	genes	defined	based	on	the	miRNAs	that	are	predicted	to	target	them.	Only	miRNAs	with	high	expression	in	normal	or	HCV-infected	liver	were	analyzed(Hou	et	al,	2011).	Evolutionarily	conserved	miRNA	target	predictions	were	extracted	from	TargetScan	v7.1(Agarwal	et	al,	2015)	(Methods).	From	left	to	right:	genes	that	are	not	conserved	targets	of	any	expressed	miRNA;	genes	that	are	targeted	by	at	least	one	expressed	miRNA;	genes	that	are	targeted	by	miR-122-5p,	miR-192/215,	let7a-i/miR-98	and	miR-199a/199b,	respectively.			
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Figure	3.		
	
	
	
	
	
	
	
a.	Volcano	plot	for	the	differential	expression	analysis	between	non-CHC	patients	and	CHC	patients	with	high	levels	of	endogenous	ISG	activation	(CHC	high	ISG).	The	X-axis	represents	the	log2	fold	expression	change	in	CHC	high	ISG	compared	to	non-CHC	patients.	The	Y-axis	represents	the	false	discovery	rate	(with	a	–log10	transformation)	of	the	differential	expression	test.	Protein-coding	genes,	candidate	long	non-coding	RNAs	(lncRNAs)	and	other	gene	categories	(including	pseudogenes	and	transcripts	with	unclear	coding	potential,	Methods)	are	represented	separately.	Only	genes	with	false	discovery	rate	(FDR)	<	10%	and	with	fold	expression	change	>	1.5	are	shown.	
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b.	Heatmap	of	the	expression	patterns	of	the	top	differentially	expressed	genes	between	non-CHC	and	CHC	high	ISG	patients.	To	select	the	top	differentially	expressed	genes,	we	set	a	fold	change	threshold	of	5	for	up-regulated	genes	and	of	1/3	for	down-regulated	genes.	The	heatmap	represents	the	Z-score	of	the	log2-transformed	RPKM	(reads	per	kilobase	of	exon	per	million	mapped	reads)	gene	expression	levels,	normalized	based	on	housekeeping	genes	(Methods).	
c.	Example	of	a	lncRNA	(NRIR(Kambara	et	al,	2014))	significantly	up-regulated	in	high	ISG	patients.	The	boxplots	represent	the	distribution	of	expression	levels	(log2-transformed	RPKM)	for	the	three	categories	of	samples.	Each	point	represents	an	individual	sample.	
d.	Boxplots	of	the	intensity	of	the	expression	change	(log2	fold)	between	non-CHC	patients	and	CHC	high	ISG	patients,	for	different	categories	of	protein-coding	genes	defined	based	on	the	miRNAs	that	are	predicted	to	target	them.	Only	miRNAs	with	high	expression	in	normal	or	HCV-infected	liver	were	analyzed(Hou	et	al,	2011).	Evolutionarily	conserved	miRNA	target	predictions	were	extracted	from	TargetScan	v7.1(Agarwal	et	al,	2015)	(Methods).	From	left	to	right:	genes	that	are	not	conserved	targets	of	any	expressed	miRNA;	genes	that	are	targeted	by	at	least	one	expressed	miRNA;	genes	that	are	targeted	by	miR-122-5p,	miR-192/215,	let7a-i/miR-98	and	miR-199a/199b,	respectively.			
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Figure	4.		
	
	
	
	
	
a.	Venn	diagram	depicting	the	intersection	between	protein-coding	genes	that	are	differentially	expressed	(FDR	<	10%,	minimum	absolute	fold	change	1.5)	between	non-CHC	patients,	CHC	patients	with	low	endogenous	ISG	levels	(CHC	low	ISG)	and	CHC	patients	with	high	endogenous	ISG	levels	(CHC	high	ISG).	Up-regulated	and	down-regulated	genes	are	analyzed	separately.		
b.	Comparison	of	the	log2-fold	expression	change	for	the	two	differential	expression	analyses:	X-axis,	CHC	low	ISG	compared	with	non-CHC	patients;	Y-axis,	CHC	high	ISG	compared	with	non-CHC	patients.	Blue:	genes	significant	in	both	comparisons;	red:	genes	significant	only	for	high	ISG	patients;	orange:	genes	significant	only	for	low	ISG	patients.	Only	protein-coding	genes	are	displayed.		
c.	Similar	to	b,	for	genes	that	are	down-regulated	only	in	the	comparison	between	non-CHC	and	CHC	low	ISG	patients.	The	vertical	dotted	lines	represent	the	absolute	fold	
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change	threshold	of	1.5	(0.58	in	log2	scale).	The	numbers	depicted	at	the	top	of	the	plot	represent	the	number	of	genes	in	each	expression	fold	change	interval	(below	1/1.5,	between	1/1.5	and	1,	between	1	and	1.5	and	above	1.5).	X-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	controls.	Y-axis:	log2	fold	expression	change	in	low	ISG	patients	compared	to	controls.	
d.	Similar	to	c,	for	genes	that	are	up-regulated	only	in	the	comparison	between	non-CHC	and	CHC	low	ISG	patients.	X-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	controls.	Y-axis:	log2	fold	expression	change	in	low	ISG	patients	compared	to	controls.	
e.	Similar	to	c,	for	genes	that	are	down-regulated	only	in	the	comparison	between	non-CHC	and	CHC	high	ISG	patients.	X-axis:	log2	fold	expression	change	in	low	ISG	patients	compared	to	controls.	Y-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	controls.		
f.	Similar	to	c,	for	genes	that	are	up-regulated	only	in	the	comparison	between	non-CHC	and	CHC	high	ISG	patients.	X-axis:	log2	fold	expression	change	in	low	ISG	patients	compared	to	controls.	Y-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	controls.			
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Figure	5.		
	
	
	
	
a.	Numbers	of	differentially	expressed	genes	following	pegIFNa/ribavirin	treatment	in	liver	biopsies	of	CHC	patients.	Gene	expression	changes	were	tested	between	paired	biopsies	from	the	same	patients,	before	and	after	treatment.	Protein-coding	genes,	lncRNAs	and	other	gene	categories	(including	pseudogenes,	transcripts	with	unclear	coding	potential	etc.)	are	displayed	separately.	We	retained	genes	with	a	false	discovery	rate	(FDR)	<	0.05,	a	minimum	absolute	fold	change	of	2	and	expression	level	(RPKM)	>1	in	at	least	one	sample.		
b.	Barplot	representing	the	proportion	of	genes	that	are	up-regulated	(left)	or	down-regulated	(right)	upon	pegIFNa	treatment	at	1,	2,	3,	4	or	5	time	points.	Different	categories	of	genes	are	color-coded.			
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Figure	6.		
	
	
	
	
	
	
a.	Differential	expression	patterns	of	the	genes	that	are	significantly	up-regulated	(FDR	<	0.05	and	minimum	absolute	fold	change	2)	following	pegIFNa/ribavirin	treatment	at	different	time	points,	in	the	comparison	between	CHC	low	ISG	and	CHC	high	ISG	patients.	X-axis:	log2	fold	expression	change	in	pegIFNa-treated	compared	to	control	biopsies.	Y-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	low	ISG	patients.	Blue	dots:	genes	also	significantly	differentially	expressed	in	the	low	ISG	vs.	high	ISG	comparison	(FDR	<0.1);	red	dots:	genes	significant	only	in	the	pegIFNa	analysis;	black	dots:	genes	not	tested	in	low	ISG	vs.	high	ISG	comparison	due	to	low	or	highly	variable	expression	levels	(Methods).	The	numbers	of	the	genes	in	each	category	are	depicted	on	the	plot	area,	with	the	same	color	code.	
b.		Similar	to	a,	for	genes	that	are	significantly	down-regulated	(FDR	<	0.05	and	minimum	absolute	fold	change	2)	following	pegIFNa	treatment	at	different	time	points.		
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c.	Histogram	of	the	difference	in	expression	levels	(log2-transformed	RPKM)	between	samples	treated	with	pegIFNa/ribavirin	and	CHC	high	ISG	samples,	for	the	genes	that	are	significantly	up-regulated	(FDR	<	0.05	and	minimum	absolute	fold	change	2)	following	pegIFNa/ribavirin	treatment	at	different	time	points.	The	differences	were	computed	between	expression	levels	averaged	across	all	relevant	samples.		
d.	Similar	to	c,	for	genes	that	are	significantly	down-regulated	(FDR	<	0.05	and	minimum	absolute	fold	change	2)	following	pegIFNa/ribavirin	treatment	at	different	time	points.		
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Figure	7.		
	
	
	
	
	
	
a.	Comparison	between	expression	levels	(log2-transformed	RPKM	values)	in	samples	obtained	after	pegIFNa/ribavirin	treatment	and	in	high	ISG	patients	(in	the	absence	of	treatment),	for	genes	predicted	to	act	as	antiviral	effectors	based	on	experiments	in	Huh7.5	cells(Metz	et	al,	2013;	Schoggins	et	al,	2011).	Only	genes	that	are	significantly	up-regulated	(FDR<0.05,	no	fold	change	threshold)	following	pegIFNa/ribavirin	treatment	are	shown.	Blue:	genes	that	are	also	significantly	differentially	expressed	(FDR<0.1)	between	low	ISG	and	high	ISG	patients.	Red:	genes	that	are	not	significant	in	the	comparison	between	low	ISG	and	high	ISG	patients	(FDR>=0.1).	Black:	genes	not	tested	in	the	comparison	between	low	ISG	and	high	ISG	patients	due	to	low	or	variable	expression	levels	(Methods).		
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b.	Expression	patterns	of	6	putative	antiviral	effector	genes	that	are	not	significantly	different	between	low	ISG	and	high	ISG	patients	(FDR>=0.1).	We	selected	genes	reported	in	both	publications(Metz	et	al,	2013;	Schoggins	et	al,	2011),	which	were	significantly	up-regulated	following	pegIFNa/ribavirin	treatment	in	our	samples,	but	not	between	low	ISG	and	high	ISG	patients.	All	resulting	genes	are	shown.	Y-axis:	log2-transformed	RPKM	levels.	X-axis:	different	categories	of	samples.	Gray:	control,	non-CHC	patients;	green:	CHC	low	ISG	samples;	orange:	CHC	high	ISG	samples;	red:	biopsies	obtained	after	pegIFNa/ribavirin	treatment,	at	different	time	points.	The	dots	represent	individual	samples.	Boxplots	are	super-imposed	over	the	individual	expression	levels.			
	 	
	 68	
Figure	8.		
	
	
	
a.	Dot-chart	representing	the	expression	changes	of	11	miRNA	host	genes	following	pegIFNa	treatment,	at	different	time	points.	Red:	significant	changes,	FDR<0.05;	orange:	FDR	between	0.05	and	0.1;	black:	FDR>0.1.		
b.	RNA-seq	coverage	profiles	along	the	miR-122	host	gene,	for	pre-treatment	and	post-treatment	biopsies	at	the	16h	time	point,	for	the	three	analyzed	individuals	(here	termed	I1,	I2	and	I3).	Gray:	normalized	read	coverage	for	baseline/pre-treatment	biopsies.	Black:	normalized	read	coverage	for	post-treatment	biopsies.	Red:	positive	difference	between	post-treatment	and	pre-treatment	biopsies.	Green:	negative	difference	between	post-treatment	and	pre-treatment	biopsies.		
c.	Dot-chart	of	the	median	fold	expression	change	following	pegIFNa/ribavirin	treatment	at	the	16h	time	point,	for	predicted	targets	of	miRNAs	whose	hosts	are	down-regulated	(red	dots)	or	of	other	miRNAs	(black	dots).	We	show	57	miRNA	families	with	at	least	100	conserved	target	genes.	As	a	control,	we	show	the	median	fold	expression	change	for	all	genes	predicted	to	be	targets	of	any	liver-expressed	miRNAs	or	of	genes	not	predicted	to	be	targeted	by	these	miRNAs	(blue	dots).		The	horizontal	bars	represent	95%	confidence	intervals	of	the	median,	constructed	with	a	bootstrap	resampling	approach	(Methods).	Only	miRNAs	with	high	expression	in	normal	or	HCV-infected	liver	were	analyzed(Hou	et	al,	2011).	Evolutionarily	conserved	miRNA	target	predictions	were	extracted	from	TargetScan	v7.1(Agarwal	et	al,	2015)	(Methods).		
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Supplementary	Figure	1.	
	
	
	
a.	Principal	component	analysis	(PCA)	of	protein-coding	gene	expression	levels,	for	untreated	CHC	and	control	samples.	The	log2-transformed	RPKM	levels	of	all	expressed	protein-coding	genes	were	used	as	input	for	the	PCA	(Methods).	Black:	non-CHC;	green:	CHC	low	ISG;	red:	CHC	high	ISG	samples.	
b.	Same	as	a,	for	protein-coding	genes	associated	with	“response	to	interferon”	Gene	Ontology	terms	(Methods).		
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Supplementary	Figure	2.		
	
	
a.	Results	of	the	Homer	transcription	factor	binding	enrichment	analysis	(Methods),	for	protein-coding	genes	that	are	up-regulated	in	CHC	low	ISG	compared	to	control	non-CHC	samples.	The	numbers	in	parentheses	represent	the	percentage	of	genes	that	have	this	motif	in	the	promoter	region	and	the	estimated	enrichment	with	respect	to	the	genomic	background.	
b.	Boxplots	of	the	intensity	of	the	expression	change	(log2	fold)	between	non-CHC	patients	and	CHC	low	ISG	patients,	for	different	categories	of	protein-coding	genes	defined	based	on	the	miRNAs	that	are	predicted	to	target	them.	Target	predictions	were	determined	with	HITS-CLIP	in	Huh7	cells(Luna	et	al,	2015).	From	left	to	right:	genes	that	are	not	conserved	targets	of	any	expressed	miRNA;	genes	that	are	targeted	by	at	least	one	expressed	miRNA;	genes	that	are	targeted	by	miR-122-5p,	miR-192/215,	let7a-i/miR-98	and	miR-15,	respectively.		
c.	Boxplots	of	the	intensity	of	the	expression	change	(log2	fold)	between	non-CHC	patients	and	CHC	low	ISG	patients,	for	different	categories	of	protein-coding	genes	defined	based	on	the	number	of	miRNA	families	that	are	predicted	to	target	them.	Only	miRNAs	with	high	expression	in	normal	or	HCV-infected	liver	were	analyzed(Hou	et	al,	2011).	Evolutionarily	conserved	miRNA	target	predictions	were	extracted	from	TargetScan	v7.1(Agarwal	et	al,	2015)	(Methods).	 	
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Supplementary	Figure	3.		
	
	
	
a.	Results	of	the	Homer	transcription	factor	binding	enrichment	analysis	(Methods),	for	protein-coding	genes	that	are	up-regulated	in	CHC	high	ISG	compared	to	control	non-CHC	samples.	The	numbers	in	parentheses	represent	the	percentage	of	genes	that	have	this	motif	in	the	promoter	region	and	the	estimated	enrichment	with	respect	to	the	genomic	background.	
b.	Same	as	a,	for	genes	down-regulated	in	CHC	high	ISG	compared	to	control	non-CHC	samples.	
c.	Barplots	representing	the	expression	patterns	of	three	categories	of	genes	(all	expressed	genes,	genes	up-regulated	in	CHC	high	ISG	patients,	and	genes	down-regulated	in	CHC	high	ISG	patients	compared	to	control	non-CHC	samples),	in	the	GTEx	tissue	transcriptome	collection.	For	each	expressed	gene,	we	scored	the	tissue	or	cell	type	in	which	its	maximum	expression	level	was	reached.	The	height	of	the	rectangles	represents	the	percentage	of	genes	that	reaches	maximum	expression	in	each	of	the	tissues.			
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Supplementary	Figure	4.		
	
	
	
	
a.	Volcano	plot	for	the	differential	expression	analysis	between	CHC	patients	with	low	levels	of	endogenous	ISG	activation	(CHC	low	ISG)	and	CHC	patients	with	high	levels	of	endogenous	ISG	activation	(CHC	high	ISG).	The	X-axis	represents	the	log2	fold	expression	change	in	CHC	high	ISG	compared	to	CHC	low	patients.	The	Y-axis	represents	the	false	discovery	rate	(with	a	-log10	transformation)	of	the	differential	expression	test.	Protein-coding	genes,	candidate	long	non-coding	RNAs	(lncRNAs)	and	other	gene	categories	(including	pseudogenes	and	transcripts	with	unclear	coding	potential,	Methods)	are	represented	separately.	Only	genes	with	false	discovery	rate	(FDR)	<	10%	and	with	fold	expression	change	>	1.5	are	shown.	
b.	Heatmap	of	the	expression	patterns	of	the	top	differentially	expressed	genes	between	CHC	low	ISG	and	CHC	high	ISG	patients.	To	select	the	top	differentially	expressed	genes,	we	set	a	minimum	absolute	fold	change	threshold	of	3.5	for	up-regulated	genes	and	of	2	for	down-regulated	genes.	The	heatmap	represents	the	Z-score	of	the	log2-transformed	RPKM	(reads	per	kilobase	of	exon	per	million	mapped	reads)	gene	expression	levels,	normalized	based	on	housekeeping	genes	(Methods).	
c.	Results	of	the	Homer	transcription	factor	binding	enrichment	analysis	(Methods),	for	protein-coding	genes	that	are	up-regulated	in	CHC	high	ISG	compared	to	CHC	low	ISG	samples.	The	numbers	in	parentheses	represent	the	percentage	of	genes	that	have	this	motif	in	the	promoter	region	and	the	estimated	enrichment	with	respect	to	the	genomic	background.			 	
●
●
●
●●
●
●● ●
●
●●
●
● ●● ●● ●
● ●●●●
●●● ●●
●
●● ●●● ● ●●●● ● ●●● ● ●●● ●● ●●●●● ●●
●
●●●●●●● ●● ● ●●● ● ● ●●●● ●●● ●● ● ●●● ●● ●● ● ●● ●● ● ●● ●●●
−4 −2 0 2 4
0
4
8
12
16
log2 fold change
−l
og
10
 F
DR
protein−coding
140 up
36 down
a
●
●
●●
● ● ●
●● ●● ● ●●●● ●● ●●
−4 −2 0 2 4
0
4
8
12
16
log2 fold change
−l
og
10
 F
DR
lncRNAs
7 up
14 down
●
●
new
known
●
●
●
● ●
●●● ●●●● ●● ●● ●● ●●●● ●●●●● ●●●●●● ●●●● ●● ●●
−4 −2 0 2 4
0
4
8
12
16
log2 fold change
−l
og
10
 F
DR
other genes
11 up
34 down
A5
84
A7
64
A7
20
C5
52
A7
48
A7
27
B2
15
B1
99
A9
91
B3
20
C1
86 C7
1
C1
06
B9
29
CHC low ISG CHC high ISG
NCAM2
SLC34A1
GRB7
MDN1
IFITM1
DDX60
IFIT2
SAMD9
IFI6
EPSTI1
ETV7
IFIT3
HERC6
OAS1
IFI44
CCL20
OAS3
IFIT1
LAMP3
CMPK2
MX1
OAS2
ISG15
RSAD2
IFI27
IFI44L
b top  genes
−1.7 0.5 2.8
Z−score log2 RPKM
ISRE (28.2% 17.5)
IRF1 (31.3% 9.4)
IRF2 (28.2% 10.1)
T1ISRE (6.9% 36.2)
IRF4 (25.9% 3.5)
PU.1−IRF (46.6% 1.6)
bZIP:IRF (16% 2.4)
PRDM1 (19.1% 1.8)
c
Differential expression, CHC low ISG vs. CHC high ISG patients
	 73	
Supplementary	Figure	5.			
	
	
	
a.	Results	of	the	Homer	transcription	factor	binding	enrichment	analysis	(Methods),	for	protein-coding	genes	that	are	up-regulated	following	4h	of	pegIFNa/ribavirin	treatment.	The	numbers	in	parentheses	represent	the	percentage	of	genes	that	have	this	motif	in	the	promoter	region	and	the	estimated	enrichment	with	respect	to	the	genomic	background.	
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b.	Same	as	a,	for	genes	that	are	up-regulated	following	16h	of	pegIFNa/ribavirin	treatment.	
c.	Same	as	a,	for	genes	that	are	up-regulated	following	48h	of	pegIFNa/ribavirin	treatment.	
d.	Same	as	a,	for	genes	that	are	up-regulated	following	96h	of	pegIFNa/ribavirin	treatment.	
e.	Same	as	a,	for	genes	that	are	up-regulated	following	144h	of	pegIFNa/ribavirin	treatment.	
f.	RNA-seq	profiles	along	the	NRIR	lncRNA,	for	pre-treatment	and	post-treatment	biopsies	at	the	4h	time	point.	Gray:	normalized	read	coverage	for	baseline/pre-treatment	biopsies.	Black:	normalized	read	coverage	for	post-treatment	biopsies.	Red:	positive	difference	between	post-treatment	and	pre-treatment	biopsies.	Green:	negative	difference	between	post-treatment	and	pre-treatment	biopsies.		
g.	Same	as	f,	for	the	lncRNA	CTD−2521M24.5	.	
h.	Same	as	f,	for	the	lncRNA	CTD−2095E4.5	.		
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Supplementary	Figure	6.		
	
	
	
	
a.	Differential	expression	patterns	of	the	genes	that	are	significantly	up-regulated	(FDR	<	0.1	and	minimum	absolute	fold	change	1.5)	in	CHC	high	ISG	patients	compared	to	CHC	low	ISG	patients.	Blue	dots:	genes	also	significantly	differentially	expressed	following	pegIFNa/ribavirin	treatment	(FDR	<0.05);	red	dots:	genes	significant	only	in	the	comparison	between	low	ISG	and	high	ISG	samples;	black	dots:	genes	not	tested	in	the	pegIFNa/ribavirin	comparison	due	to	low	or	highly	variable	expression	levels	(Methods).	X-axis:	log2	fold	expression	change	in	pegIFNa-treated	compared	to	control	biopsies.	Y-axis:	log2	fold	expression	change	in	high	ISG	patients	compared	to	low	ISG	patients.	The	numbers	of	the	genes	in	each	category	are	depicted	on	the	plot	area,	with	the	same	color	code.	
b.		Similar	to	a,	for	genes	that	are	significantly	down-regulated	(FDR	<	0.1	and	minimum	absolute	fold	change	1.5)	in	CHC	low	ISG	and	CHC	high	ISG	patients.		
c.	Histogram	of	the	difference	in	expression	levels	(log2-transformed	RPKM)	between	samples	treated	with	pegIFNa/ribavirin	and	CHC	high	ISG	samples,	for	the	genes	that	
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are	up-regulated	(FDR	<	0.1	and	minimum	absolute	fold	change	1.5)	in	CHC	high	ISG	patients	compared	to	CHC	low	ISG	patients.	The	differences	were	computed	between	expression	levels	averaged	across	all	relevant	samples.		
d.	Similar	to	c,	for	genes	that	are	significantly	down-regulated	(FDR	<	0.1	and	minimum	absolute	fold	change	1.5)	in	CHC	high	ISG	patients	compared	to	CHC	low	ISG	patients.		
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Supplementary	Figure	7.		
	
	
a.	RNA-seq	profiles	along	the	miR-331/miR-3685	host	gene,	for	pre-treatment	and	post-treatment	biopsies	at	the	16h	time	point,	for	the	three	analyzed	individuals	(I1,	I2	and	I3).	Gray:	normalized	read	coverage	for	baseline/pre-treatment	biopsies.	Black:	normalized	read	coverage	for	post-treatment	biopsies.	Red:	positive	difference	between	post-treatment	and	pre-treatment	biopsies.	Green:	negative	difference	between	post-treatment	and	pre-treatment	biopsies.		
b.	Same	as	a,	for	the	miR-192/miR-194	host	gene.	
c.	Same	as	a,	for	the	miR-146a	host	gene.	
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Supplementary	Table	Legends	
Supplementary	Table	1.		
	
	
		This	table	describes	the	patient	characteristics.	The	first	Excel	sheet	("Patients	-	endogenous	ISG")	contains	the	characteristics	of	the	patients	classified	as	"CHC	low	ISG",	"CHC	high	ISG"	and	of	control	(non-CHC)	patients.		The	second	Excel	sheet	presents	the	characteristics	of	the	patients	analyzed	in	the	pegIFNa	time	series.		
Supplementary	Table	2.		This	table	presents	the	results	of	the	differential	expression	analyses	comparing	control	non-CHC	samples,	CHC	low	ISG	samples	and	CHC	high	ISG	samples.	Each	analysis	is	presented	in	a	separate	Excel	sheet.		
Supplementary	Table	3.		This	table	provides	the	gene	ontology	enrichment	results	for	the	comparison	between	non-CHC	patients,	CHC	low	ISG	and	CHC	high	ISG	patients.	These	results	were	obtained	with	GOrilla	(Eden	et	al.,	Bioinformatics,	2009).	The	enrichment	test	was	performed	only	for	the	"biological	process"	GO	category.	 		
Supplementary	Table	4.		This	table	provides	information	regarding	the	set	of	liver-expressed	miRNAs	and	their	targets	predicted	by	TargetScan	that	we	analyzed	in	this	manuscript	(Methods).	We	also	provide	miRNA	target	predictions	from	a	previous	publication(Luna	et	al,	2015)	in	a	separate	Excel	sheet.				
Supplementary	Table	5.		This	table	presents	a	comparison	between	genes	that	are	differentially	expressed	following	HCV	infection	in	Huh7.5	cells	(previously	published	dataset(Walters	et	al,	2009))	and	those	that	we	found	to	be	differentially	expressed	following	HCV	infection	in	liver	biopsies.		
Biopsy No Patient No Age Sex Patient classification HCV GT Viral load, log IU/mL METAVIR Comment
A584 1 37 m CHC	low	ISG 3 4.9 A1/F2
A764 3 38 m CHC	low	ISG 4 4.08 A2/F2
A720 4 51 f CHC	low	ISG 1 6.82 A1/F2
C552 5 49 f CHC	low	ISG 4 5.68 A2/F2
A748 8 30 m CHC	low	ISG 3 7.07 A2/F2
A727 9 57 f CHC	low	ISG 1 5.95 A2/F2
B215 16 34 m CHC	low	ISG 3 5.56 A2/F2
A991 6 42 f CHC	high	ISG 3 5.49 A1/F2
B199 7 41 m CHC	high	ISG 3 5.66 A1/F2
B320 17 57 f CHC	high	ISG 2 5.18 A2/F2
B929 19 38 f CHC	high	ISG 1 5.05 A1/F1 no	therapy
C71 20 41 f CHC	high	ISG 1 7.14 A1/F1 no	therapy
C106 21 51 m CHC	high	ISG 4 5.97 A1/F2 no	therapy
C186 22 47 f CHC	high	ISG 1 6.01 A1/F1 SVR	24	after	triple	therapy	with	pegIFN,	Ribavirin	and	boceprevir
B986 23 49 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
paired	tumor	and	non-tumor	biopsy,	metastase	of	brest	cancer,	
normal	histology	of	non-tumor	biopsy
C145 25 43 f control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
C173 26 62 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
paired	tumor	and	non-tumor	biopsy,	metastase	of	lung	cancer,	
normal	histology	of	non-tumor	biopsy
C369 28 37 m control	(non-CHC) unclear	hepatopathie,	isolated	GGT	elevation,	normal	histology	
C250a 27 80 m control	(non-CHC)
C51a 24 63 f control	(non-CHC)
Baseline 4-week 12-week 4-week 12-week Follow-up
A	584 A	584-2 1 2 37 m 3 4.9 neg neg RVR cEVR SVR A1/F2 4h pegIFN-α2b
A	609 A	609-2 2 3 54 f 2 4.95 neg neg RVR cEVR SVR A3/F3 4h pegIFN-α2b
A	764 A	764-2 3 5 38 m 4 4.08 1.66 neg non-RVR cEVR SVR A2/F2 4h pegIFN-α2b
A	720 A	720-2 4 6 51 f 1 6.82 3.52 neg non-RVR cEVR SVR A1/F2 4h pegIFN-α2b
C552 C591 5 - 49 f 4 5.68 2.75 neg non-RVR cEVR ongoing A2/F2 16h pegIFN-α2b
A	991 A991-2 6 8 42 f 3 5.49 neg neg RVR cEVR SVR A1/F2 16h pegIFN-α2b
B	199 B	217 7 9 41 m 3 5.66 neg neg RVR cEVR SVR A1/F2 16h pegIFN-α2b
A	748 A	748-2 8 10 30 m 3 7.07 neg neg RVR cEVR SVR A2/F2 48h pegIFN-α2b
A	727 A	727-2 9 11 57 f 1 5.95 neg neg RVR cEVR SVR A2/F2 48h pegIFN-α2b
B	254 B	284 10 12 37 m 3 6.72 1.28 neg non-RVR cEVR SVR A3/F2 48h pegIFN-α2b
A	616 A	616-2 11 13 62 m 4 7.16 neg neg RVR cEVR SVR A3/F4 96h pegIFN-α2b
B	136 B	178 12 14 43 m 1 5.6 1.63 neg non-RVR cEVR SVR A3/F2 96h pegIFN-α2b
B	283 B	304 13 15 40 m 1 5.16 1.41 neg non-RVR cEVR SVR A3/F4 96h pegIFN-α2b
A	707 A	707-2 14 16 25 f 1 2.64 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
A	972 A	972-2 15 17 70 m 2 6.86 1.84 neg non-RVR cEVR SVR A2/F3 144h pegIFN-α2b
B	215 B	247 16 18 34 m 3 5.56 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
B	320 B	371 17 19 57 f 2 5.18 neg neg RVR cEVR SVR A2/F2 144h pegIFN-α2b
B	346 B	401 18 20 57 m 1 6.54 4.59 3.33 non-RVR EVR Interrupted A3/F4 144h pegIFN-α2b
HCV GTBiopsy No Patient No Patient No (Dill et al., JC, 2014I) Age Sex
Viral load, log IU/mL Response
METAVIR Time point Medication
	 79	
Supplementary	Table	6.		This	table	presents	the	results	of	the	differential	expression	analyses	comparing	pre-treatment	and	post-treatment	biopsies	at	different	time	points	during	the	pegIFNa/ribavirin	treatment.	Each	analysis	is	presented	in	a	separate	Excel	sheet.	
	
Supplementary	Table	7.		This	table	provides	the	gene	ontology	enrichment	results	for	the	differential	expression	analyses	comparing	pre-treatment	and	post-treatment	biopsies	at	different	time	points	during	the	pegIFNa/ribavirin	treatment.	Each	analysis	is	presented	in	a	separate	Excel	sheet.	
	
Supplementary	Table	8.		This	table	provides	the	list	of	genes	that	are	differentially	expressed	following	IFNa	treatment,	at	one	or	more	time	points.	For	each	gene,	we	extract	the	time-points	in	which	it	is	up-regulated	or	down-regulated.			
Supplementary	Table	9.		This	table	provides	a	comparison	between	genes	that	are	differentially	expressed	between	low	ISG	and	high	ISG	patients	and	following	pegIFNa/ribavirin	treatment,	at	different	time	points.		
Supplementary	Table	10.		This	table	presents	the	results	of	the	differential	expression	analyses	(between	low	ISG	and	high	ISG	patients,	or	following	pegIFNa/ribavirin	treatment	biopsies)	for	lists	of	genes	previously	shown	to	have	a	negative	effect	on	HCV	replication	in	Huh7.5	cells(Metz	et	al,	2013;	Schoggins	et	al,	2011).			
Supplementary	Table	11.	This	table	presents	the	list	of	miRNA	host	genes	analyzed	in	this	manuscript,	highlighting	those	that	are	differentially	expressed	following	pegIFNa/ribavirin	treatment	(FDR<0.05).			 	
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4. Conclusion		 In	 the	 liver,	 cell-intrinsic	 adaptive	 changes	 to	HCV	 infections	 are	difficult	 to	detect	because	of	the	gene	expression	changes	induced	by	the	innate	immune	response,	mainly	through	IFNs,	can	mask	the	more	subtle	cell-intrinsic	changes	induced	be	HCV	directly	in	infected	cells.	Due	to	a	genetic	polymorphism	in	the	IFNl4	gene,	ISG	induction	in	humans	is	 highly	 variable110,	 116.	 To	 specifically	 identify	 dysregulated	 genes	 other	 than	 IFN	stimulated	genes,	we	selected	a	set	of	liver	biopsies	from	patients	without	endogenous	ISG	 induction	 and	 compared	 gene	 expression	 in	 these	 “ISG	 low”	 samples	 with	 global	gene	 expression	 in	 a	 set	 of	 control	 samples	 from	non-infected	patients	with	 a	 normal	liver.	 We	 found	 that	 gene	 expression	 changes	 between	 uninfected	 liver	 samples	 and	biopsies	without	detectable	 ISG	expression	mainly	reflect	 the	presence	of	 immune	cell	infiltrates	 in	 the	 latter	 group.	 Contrary	 to	 our	 expectations,	 we	 could	 not	 detect	expression	 changes	 of	 genes	 involved	 in	 cellular	 responses	 to	 HCV	 described	 in	 cell	culture.	 For	 example,	 a	previous	 large-scale	 analysis	 of	differential	 gene	 expression	 in	HCV-infected	Huh-7.5	cells	revealed	that	860	genes	showed	a	2-fold	or	higher	change	in	expression.	 Gene	 ontology	 analysis	 revealed	 that	 many	 of	 them	 are	 involved	 in	 DNA	damage/oxidative	 stress	 response,	 cytochrome	 c	 release,	 cell	 death,	 cell	 cycle	 and	cytokine/growth	factor	signalling	122.		Unlike	this	in	vitro	analysis,	our	in	vivo	differential	expression	analyses	did	not	reveal	enrichments	for	these	functional	categories	of	genes.	Using	 a	 targeted	 approach	 by	 specifically	 analysing	 genes	 previously	 reported	 to	 be	changed	 in	 HCV-infected	 Huh-7.5	 cells	 122,	 we	 could	 indeed	 identify	 a	 core	 set	 of	 25	genes	that	are	differentially	expressed	following	HCV	infection	in	both	Huh	7.5	cells	and	in	 liver	 samples	 from	 patients	 without	 IFN	 system	 activation.	 This	 common	 gene	 set	included	several	cell	cycle	associated	genes,	such	as	UBD,	ITIH1	and	BIRC3.	25	out	of	860	genes	seems	to	be	a	very	low	number,	but	statistical	analysis	of	the	data	revealed	that	this	 is	 significantly	more	 than	expected	by	 chance	alone.	We	conclude	 that	our	 in	vivo	analysis	 confirms	 the	 induction	 of	 a	 small	 but	 significant	 number	 of	 genes	 that	 have	been	described	to	be	induced	by	HCV	in	cell	culture	experiments.	The	huge	differences	between	 in	vivo	 and	 in	vitro	could	 be	 due	 to	 the	 very	 high	 viral	 concentration	 in	 cell	culture:	 the	number	of	HCV	virions	per	 infected	cell	 is	between	1	and	8	 in	 the	human	liver,	but	can	be	as	high	as	500	to	1000	in	the	Huh-7.5	cell	culture	model.	Moreover	only	1-55%	of	the	hepatocytes	in	the	human	liver	are	HCV	positive109.	Therefore,	changes	in	
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infected	 hepatocytes	 could	 be	masked	 by	 unchanged	 gene	 expression	 in	 non-infected	hepatocytes	and	non-parenchymal	liver	cells.		 The	 second	aim	of	 the	work	was	 to	 characterize	 IFN	 stimulated	 changes	 in	 the	liver	 trancriptome	 of	 patients	 with	 chronic	 hepatitis	 C	 (CHC)	 and	 an	 activated	endogenous	IFN	system.	To	do	this,	we	contrasted	gene	expression	levels	between	non-CHC	 control	 samples	 and	 CHC	 samples	 with	 high	 ISG	 expression	 (“ISG	 high”).	 We	observed	503	protein-coding	genes,	80	candidate	long	non-coding	RNAs	and	125	other	genes	differentially	 expressed	genes	 in	 the	 latter	group.	 	As	expected,	 the	most	highly	up-regulated	protein-coding	genes	were	known	ISGs.	The	up-regulated	long	non-coding	RNAs	 included	 a	 previously	 described	 interferon-inducible	 transcript,	 NRIR	 123.	However,	most	of	the	lnc	RNAs	have	not	been	described	previously	in	the	context	of	HCV	infections,	and	their	function,	if	any,	remains	to	be	explored.		 The	third	aim	of	the	work	addressed	a	longstanding	conundrum	in	the	field:		Despite	a	strong	induction	of	hundreds	of	ISGs	the	endogenous	IFN	system	is	ineffective	against	HCV,	whereas	therapies	with	pegIFNα	were	curative	in	many	patients.	Two	alternative	explanations	were	explored:	Either	some	critical	ISGs	are	exclusively	induced	by	pegIFNα,	or	pegIFNα	induces	the	same	ISGs	but	at	a	higher	level	than	the	endogenous	IFNs.	Our	data	clearly	indicate	that	the	second	explanation	is	more	likely.	The	same	set	of	ISGs	was	induced	by	pegIFNa	and	the	endogenous	IFN	system,	but	with	lower	induction	levels	in	the	latter.			 The	forth	aim	of	the	study	was	to	characterize	the	expression	dynamics	of	non-coding	 genes,	 including	 long	 non-coding	 RNAs	 and	miRNA	 transcripts	 in	 response	 to	HCV	 infections	 and	 to	pegIFNα	 treatments.	Our	 analysis	 revealed	 that	 numerous	non-coding	transcripts	are	down-regulated,	in	particular	at	the	16h	time	point.	These	down-regulated	 genes	 include	11	miRNA	 “host”	 genes.	Most	 interesting	 of	 them	 is	miR-122,	because	 it	 is	 an	 essential	 host	 factor	 for	 HCV	 replication29.	 Detailed	 functional	experiments	 in	Huh7	cells	brought	evidence	that	HCV	 infection	 leads	to	significant	de-repression	of	miR-122	target	genes	due	to	this	sponging	effect1.	At	first	sight,	our	in	vivo	transcriptomic	analysis	appeared	to	confirm	this	observation,	as	miR-122	target	genes	had	higher	expression	levels	in	HCV-infected	compared	to	control	biopsies.	However,	a	closer	 look	 revealed	 the	 same	pattern	 for	 other	miRNAs	 highly	 expressed	 in	 the	 liver	
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(e.g.,	miR-192,	let-7).	Because	HCV	does	not	bind	these	other	miRNAs,	this	observation	cannot	be	simply	explained	by	a	sponging	effect.		It	 has	 been	 reported,	 that	 hundreds	 of	 lncRNAs	 are	 induced	 by	 pegIFNα	 treatment	 in	Huh7	cells	124	and	PHH123.	RNA-Seq	analysis	of	Huh7	cells	infected	with	the	JFH-1	strain	of	HCV	revealed	that	the	expression	of	more	than	500	lncRNAs	is	altered	in	infected	cells	125.	We	could	not	confirm	this	huge	impact	of	HCV	on	lncRNA	expression	in	vivo.	In	our	analysis	 we	 found	 only	 14	 lncRNAs	 in	 “ISG	 	 low”	 and	 80	 lncRNAs,	 including	 the	previously	 published	NRIR123	 in	 “ISG	 high”	 samples	 to	 be	 altered	 upon	HCV	 infection.	Moreover,	 even	 in	 the	 samples	 with	 maximal	 stimulation	 during	 pegIFNα	 treatment,	only	88	lncRNAs	were	differentially	expressed.	As	with	cell-intrinsic	changes	discussed	above,	a	possible	explanation	lies	in	the	massive	“over-infection”	of	cells	present	in	the	fully	 infectious	HCV	cell	 culture	system.	 In	addition,	 these	differences	between	 in	vitro	and	 in	vivo	experiments	 	could	also	result	 from	a	different	definition	of	 lncRNAs,	since	we	used	very	stringent	criteria.	To	avoid	annotating	alternative	un-translated	regions	or	introns	of	protein-coding	genes	as	independent	lncRNAs,	we	filtered	the	set	of	de	novo-predicted	lncRNAs	based	on	their	distance	to	Ensembl-annotated	protein-coding	genes.	We	retained	only	lncRNA	candidates	that	had	no	sense	overlap	with	Ensembl-annotated	protein-coding	genes	and	that	were	at	least	10	kilobases	(kb)	away	from	protein-coding	gene	coordinates.	We	also	discarded	loci	with	an	exonic	length	below	200	bp	(for	multi-exonic	loci)	or	500	bp	(for	mono-exonic	loci).	We	further	excluded	loci	overlapping	with	RNA	repeats	or	with	UCSC-annotated	retro-transposed	gene	copies	over	more	than	10%	of	 their	 length.	 These	 stringent	 criteria	might	 have	missed	 some	 lncRNAs,	 but	we	 are	convinced	that	many	of	 the	previously	reported	HCV	induced	 lncRNAs	were	not	bona-fide	lncRNAs	according	to	current	bio-informatic	standards.				 In	 conclusion,	 our	 comprehensive	 transcriptome	 analysis	 of	 liver	 biopsy	 from	patients	with	CHC	revealed	that	HCV	has	no	strong	effect	on	the	homeostasis	of	infected	cells,	that	the	endogenous	IFN	response	is	qualitatively	similar	to	pegIFNα	treatment	but	too	 weak	 to	 clear	 the	 infection	 and	 that	 IFN	 down-regulates	 miRNA	 precursor	transcripts,	thereby	fine-tuning	ISG	expression.					
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